Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

专利摘要:

公开号:AU2010276460A1
申请号:U2010276460
申请日:2010-12-17
公开日:2011-02-17
发明作者:Malcolm Clive Carter；George Stuart Cockerill；Stephen Barry Guntrip；Karen Elizabeth Lackey；Kathryn Jane Smith
申请人:Novartis AG；
IPC主号:C07D471-04

专利说明:
BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS The present invention relates to a series of substituted heteroaromatic 5 compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition. 10 Protein tyrosine kinases catalyse the phosphorylation of specific tyrosyl residues in various proteins involved in the regulation of cell growth and differentiation (A.F. Wilks, Progress in Growth Factor Research, 1990, 2, 97-111; S.A. Courtneidge, Dev. Supp.l, 1993, 57-64; J.A. Cooper, Semin. Cell Biol., 1994, 5(61, 377-387; R.F. Paulson, Semin. Immunol., 1995, 7(4), 267-277; A.C. Chan, Curr. Opin. Immunol., 15 1996, 8(3), 394-401). Protein tyrosine kinases can be broadly classified as receptor (e.g. EGFr, c-erbB-2, c-met, tie-2, PDGFr, FGFr) or non-receptor (e.g. c src, Ick, zap70) kinases. Inappropriate or uncontrolled activation of many of these kinase, i.e. aberrant protein tyrosine kinase activity, for example by over expression or mutation, has been shown to result in uncontrolled cell growth. 20 Aberrant activity of protein tyrosine kinases, such as c-erbB-2, c-src, c-met, EGFr and PDGFr have been implicated in human malignancies. Elevated EGFr activity has, for example, been implicated in non-small cell lung, bladder and head and neck cancers, and increased c-erbB-2 activity in breast, ovarian, gastric and 25 pancreatic cancers. Inhibition of protein tyrosine kinases should therefore provide a treatment for tumours such as those outlined above. Aberrant protein tyrosine kinase activity has also been implicated in a variety of other disorders: psoriasis, (Dvir et al, J.CeIl.Biol; 1991, 113, 857-865), fibrosis, 30 atherosclerosis, restenosis, (Buchdunger et al, Proc.Natl.Acad.Sci. USA; 1991, 92, 2258-2262), auto-immune disease, allergy, asthma, transplantation rejection - A (Klausner and Samelson, Cell; 1991, 64, 875-878), inflammation (Berkois, Blood; 1992, 79(9), 2446-2454), thrombosis (Salari et al, FEBS; 1990, 263(l), 104-108) and nervous system diseases (Ohmichi et al, Biochemistry, 1992, 31, 4034-4039). Inhibitors of the specific protein tyrosine kinases involved in these diseases eg 5 PDGF-R in restenosis and EGF-R in psoriasis, should lead to novel therapies for such disorders. P561ck and zap 70 are indicated in disease conditions in which T 2 cells are hyperactive e.g. rheumatoid arthritis, autoimmune disease, allergy, asthma and graft rejection. The process of angiogenesis has been associated with a number of disease states (e.g. tumourogenesis, psoriasis, rheumatoid arthritis) and this has been shown to be controlled through the action of a number of receptor tyrosine kinases (L.K. Shawver, DDT, 1997, 2(2), 50-63). It is therefore a general object of the present invention to provide compounds suitable for the treatment of disorders mediated by protein tyrosine kinase activity, and in particular treatment of the above mentioned disorders. In addition to the treatment of tumours, the present invention -envisages that other disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition, including preferential inhibition, of the appropriate protein tyrosine kinase activity. Broad spectrum inhibition of protein tyrosine kinase may not always provide optimal treatment of, for example tumours, and could in certain cases even be detrimental to subjects since protein tyrosine kinases provide an essential role in the normal regulation of cell growth. It is another object of the present invention to provide compounds which preferentially inhibit protein tyrosine kinases, such as EGFr, c-erbB-2, c-erbB-4, c met, tie-2, PDGFr, c-src, Ick, Zap70, and fyn. There is also perceived to be a benefit in the preferential inhibition involving small groups of protein tyrosine kinases, for example groups including two or more of c-erbB-2, c-erbB-4, EGF-R, Ick and zap70. A further object of the present invention is to provide compounds useful in the treatment of protein tyrosine kinase related diseases which minimise undesirable side-effects in the recipient. The present invention relates to heterocyclic compounds which may be used to treat disorders mediated by protein tyrosine kinases and in particular have anti-cancer properties. More particularly, the compounds of the present invention are potent inhibitors of protein tyrosine kinases such as such as EGFr, c-erbB-2, c-erbB-4, c 0:docsPatentsMARSPECSPG3416au.DOC 3 met, tie-2, PDGFr, c-src, Ick, Zap70, and fyn, thereby allowing clinical management of particular diseased tissues. The present invention envisages, in particular, the treatment of human malignancies, 5 for example breast, non-small cell lung, ovary, stomach, and pancreatic tumours, especially those driven by EGF-R or erbB-2, using the compounds of the present invention. For example, the invention includes compounds which are highly active against the c-erbB-2 protein tyrosine kinase often in preference to the EGF receptor kinase hence allowing treatment of c-erbB-2 driven tumours. However, the I invention also includes compounds which are highly active against both c-erbB-2 and EGF-R receptor kinases hence allowing treatment of a broader range of tumours. More particularly, the present invention envisages that disorders mediated by protein tyrosine kinase activity may be treated effectively by inhibition of the appropriate protein tyrosine kinase activity in a relatively selective manner, thereby minimising potential side effects. Accordingly, the present invention provides a compound of formula (1) HN Y N 11 (I) N H or a salt or solvate thereof; wherein Y is CR' and Vis N; or Y is CR 1 and V is CR 2 ; R1 represents a group CHaSO 2
CH
2
CH
2
NHCH
2 -Ar-, wherein Ar is selected from furan and thiazole, each of which may optionally be substituted by one or two halo, C 4 alkyl or C 14 alkoxy groups; 0:docsPatentsWMARSPECSPG3416au.DOC 4
R
2 is hydrogen or C14 alkoxy; or R 2 is halo;
R
3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;
R
4 is halo or C4 alkoxy or is not present; wherein either (a) R 3 represents 3-fluorobenzyloxy; and/or (b) R 4 is selected from halo and is substituted in the 3-position of the phenyl ring; and halo represents fluoro, chloro or bromo. Solvates of the compounds of formula (1) are also included within the scope of the present invention. The definitions for Y and V thus give rise to a number of possible basic ring systems for the compounds of formula (1). In particular the compounds may contain the following basic ring systems: N ~N (2) (6) t N N *_ N) (6 It will be seen that for compounds containing the basic ring system (2) the group R' will be at the 6- position; such compounds are of particular interest in the context of c-erbB-2 activity. Alkyl groups containing three or more carbon atoms may be straight, branched or cyclised; preferably they are straight or branched. References to a specific alkyl group such as "butyl" is intended to refer to the straight chain (n-) isomer only. References to other generic terms such as alkoxy, alkylamino etc. are to be interpreted analogously. O:docsPatentsMARSPECSPG3416 auDOC 5 Suitable values for the various groups listed above within the definitions for R", R 2 ,
R
4 and R 5 are as follows: halo is fluoro, chloro or bromo, more preferably fluoro or chloro; C14 alkyl is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; preferably it is methyl, ethyl, propyl, isopropyl or butyl, more preferably methyl; C14 alkoxy is, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy; preferably it is methoxy, ethoxy, propoxy, isopropoxy or butoxy; more preferably it is methoxy. In an especially preferred embodiment Y is CR' and V is CR 2 (ring system (2) above). In a further especially preferred embodiment Y is CR' and V is N (ring system (6) above). In a preferred embodiment R 2 represents hydrogen or C14 alkoxy. In a more preferred embodiment R 2 represents hydrogen or methoxy. In a further preferred embodiment R 2 represents halo; more preferred R 2 is fluoro. In a preferred embodiment the group Ar is substituted by one halo, C14 alkyl or C 14 alkoxy group. In a more preferred embodiment the group Ar is substituted by a C14 alkyl group. In a further more preferred embodiment the group Ar does not carry any optional substituents. In a most preferred embodiment Ar represents unsubstituted furan or thiazole. The side chain CH 3
SO
2
CH
2
CH
2
NHCH
2 may be linked to any suitable position of the group Ar. Similarly, the group R 1 may be linked to the carbon atom carrying it from any suitable position of the group Ar. O:docsPatentsMARSPECSPG3416au-DOC 6 In a preferred embodiment, when Ar represents furan the side chain
CH
3
SO
2
CH
2
CH
2
NHCH
2 is in the 4-position of the furan ring and the link to the carbon atom carrying the group R' is from the 2-position of the furan ring. In another preferred embodiment, when Ar represents furan the side chain
CH
3
SO
2
CH
2
CH
2
NHCH
2 is in the 3-position of the furan ring and the link to the carbon atom carrying the group R" is from the 2-position of the furan ring. In a most preferred embodiment, when Ar represents furan the side chain
CH
3
SO
2
CH
2
CH
2
NHCH
2 is in the 5-position of the furan ring and the link to the carbon atom carrying the group R' is from the 2-position of the furan ring. In a further most preferred embodiment, when Ar represents thiazole the side chain
CH
3
SO
2
CH
2
CH
2
NHCH
2 is in the 2-position of the thiazole ring and the link to the carbon atom carrying the group R' is from the 4-position of the thiazole ring. In a preferred embodiment R 3 represents benzyl, pyridylmethyl, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl. In a more preferred embodiment R 3 represents benzyloxy, fluorobenzyloxy (especially 3-fluorobenzyloxy), benzyl, phenoxy and benzenesulphonyl. In a further more preferred embodiment R 3 represents bromobenzyloxy (especially 3-bromobenzyloxy). In a further preferred embodiment R 4 is not present. In a further preferred embodiment R 4 is selected from halo or C 1 4 alkoxy; especially chloro, fluoro or methoxy. In a more preferred embodiment Rrepresents halo, especially 3-fluoro. In an especially preferred embodiment the phenyl ring together with R 4 represents methoxyphenyl, fluorophenyl, or chlorophenyl. 0;docsPatentsMARsPECSPG3416au.DOC 7 in a more especially preferred embodiment the phenyl ring together with R 4 represents methoxyphenyl or fluorophenyl. In an especially preferred embodiment the phenyl ring together with the substituent(s) R 3 and R 4 represents (3-fluorobenzyloxy)phenyl. In another especially preferred embodiment the phenyl ring together with the substituent(s) R 3 and R 4 represents (3-fluorobenzyloxy)-3-methoxyphenyl. In a more especially preferred embodiment the phenyl ring together with the substituent(s) R 3 and R 4 represents 3-fluorobenzyloxy-3-chlorophenyl, benzyloxy-3 chlorophenyl, (benzyloxy)-3-fluoropheny, or (3-fluorobenzyloxy)-3-fluorophenyl. Preferred compounds of the present invention include: (4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl) furan-2-yl)-pyrido[3,4-djpyrimidin-4-yl)-amine; (4-(3-Fluorobenzyloxy-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl) furan-2-y)-pyrido[3,4-d]pyrimidin-4-yl)-amine; N-{4-[(3-Fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl) 2-furyl]-4-quinazolinamine; N-{4-[(3-Fluombenzyl)oxy]-3-methoxyphenyl}-6-[5-({[2 (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{4-[(3-Fluorobenzyl)oxy-3-methoxyphenyl}-6-[2-({[2 (methanesulphonyl)ethyljamino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-{4-[(3-Fluorobenzyl)oxylphenyl}-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl) 1,3-thiazol4-yl]-4-quinazolinamine; N-[4-(Benzyloxy)-3-fluorophenyl]-6-[2-({[2-(methanesulphonyl)ethyl]amino)methyl) 1,3-thiazol-4-yl]-4-quinazolinamine; N-{3-Fluoro4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2 (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-({[2 (methanesulphonyl)ethyllamino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-(3-Fluoro-4-benzyloxyphenyl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl) 1, 3 -thiazol-4-yl]-4-quinazolinamine; O:docsPatentsMARSPECSPG3416au.DOC 8 N-(3-Chloro-4-benzyloxyphenyl)-6-[2-({[2-(methanesulphonyl)ethyl]amino}methyl) 1,3-thiazol-4-yl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxyphenyl}-6-[5-({[2 (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof. Other preferred compounds of the present invention include the following (in groups denoted hereafter as Lists I to 9): List I (4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphony-ethylamino)methy) thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl) thiazol-5-yl)-pyrido[3,4-d]pyrimidin-4-y)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)methyl) thiazol-2-yI)-pyrido[3,4-djpyrimidin-4-yI)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphony-ethylamino)methyl) thiazol-2-yi)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyi-ethylamino)methyl) furan-2-yl)-quinazolin-4-yl)-amine; (4-(3-Fl uorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylam ino)methyl) thiazol-4-yl)-quinazolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl) thiazol-5-yl)-quinazolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-pheny)-(6-(4-((2-methanesulphonyl-ethylamino)methyl) thiazol-2-yl)-quinazolin-4-yl)-amine;
(
4
-(
3 -Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl) thiazol-2-yI)-quinazolin-4-yl)-amine; List 2
(
4 -Benzyloxy-3-chlorophenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl) furan-2-yl-pyrido[3,4-d]pyrimidin-4-y)-amine; (4-(3-Fluoro-benzyloxy)-3-chlorophenyl)-(6-(5-((2-methanesulphonyl ethyla mino)methyl)-fu ran-2-yl)-pyrido[3,4-djpyrimidin-4-yl)-a mine; 0:docsPatentsMARSPECSPG3416au.DOC 9 (4-Benzyloxy-3-bromophenyl )-(6-(5-((2-methanesu lphonyl-ethylam ino)methyl )-furan 2-yl)-pyrido[3,4-d]pyrimidin-4-yI)-amine; (4-(3-Fluoro-benzyloxy)-3-bromophenyl)(6-(5-((2-methanesulphonyl ethylamino)methyl-furan-2-yI)-pyrido[3,4-d]pyrimidin-4-yI)-amine; (4-Benzyloxy-3-fluorophenyl)-(6-(5-((2-methanesul phonyl-ethyla mino)methyl)-furan 2-yl)-pyrido[3,4-d]pyrimidin-4-yI)-amine; (4-(3-Fluoro-benzyloxy-3-fluorophenyl)-(6-(5-((2-methanesulphonyl ethylamino)methyl)-fu ra n-2-yl)-pyrido[3,4-d]pyrimidin-4-yI)-amine; List 3 (4-Benzyloxy-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl) thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yI)-amine; (4-(3-Fluoro-benzyloxy)-3-chIorophenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-th iazol-4-yl )-pyrido[3,4-d] pyrimid in-4-yl)-a mine;
(
4 -Benzyloxy-3-bromophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl) thiazol-4-y)-pyrido[3,4-djpyrimidin-4-yl)-amine: (4-(3-Fluoro-benzyloxy)-3-b romophenyl)-(6-(2-((2-metha nesu I phonyl ethylamino)methyl)-th iazol-4-y)-pyrido[3,4-d]pyrimidin-4-yl)-am ine; (4-Benzyloxy-3-fluorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol 4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluoro-benzyloxy)-3-fluorophenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-d]pyrimid in-4-y)-amine; List 4 (4-Benzyloxy-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl) thiazol-4-yI)-quinazolin-4-yl)-amine (4-(3-Fluoro-benzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-th iazol-4-yJ)-quinazolin-4-yl-a mine; (4-Benzyloxy-3-bromophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl) thiazol-4-yl)-quinazolin-4-yI)-amine; (4-(3-Fluoro-benzyloxy)-3-bromophenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-y)-amine; O:docsPatentsMARSPECSPG3416au.
DOC
10 List 5
(
4 -Benzyloxy-3-bromophenyi)-(6-(5-((2methanesu phonyl-ethylamino)-methy9-fu ran 2-yI)-quinazolin-4-yi)-amine; (4-(3-Flunro-benzyloxy-3-bromophenyl)-(6-(s-((2metha nesu Iphonyl-ethyla mino) methyl)-fu ra n-2-yi)-quinazol i n-4-yI)-a mine; List 6 N-[4-(Benzyloxy)-3-chlopheny-methoy6-[({[2 (methanesulphonyl)ethyljam inolmethyl)-2-furylJ-4-qu inazol inami ne;
N-[
4 -(3-Fluoro-benzyloxy)-3-chlorophenyIJ-7-methoxy6-[5({[2 (methanesulphonyl)ethyl]a minolmethyl )-2-furyl]-4-qu inazolinamine; N-[4-Benzyloxy-3-bromopheny-7-methoy6-5([2. (metha nesu Iphonyl )ethylja mino~methyl )-2-furyl]-4-q uinazolinamine; N-[4-(3-Fiuoro-benzyloxy)-3-bromopheny-r-methaxy-6[5((2 (methanesulphonyl)ethylamino}methyl )-2-fu rI-4-qu inazolinamine; N-[4-Benzyloxy-3-fiuorophenylj-z-methoxy-645([2. (methanesu Iphonyl)ethyi]amino~methyl)-2-fu ryfl-4-quinazolina mine; N-[4-(3-Fluoro-benzyloxy)-3-fuorophenylpp7methoxy-6-[([2. (methanesu I phonyl)ethyljamino}methyl)-2-fu ryIJ-4-qu inazolina mine; List 7 N-[4-(Benzyfoxy)-3-chlorophenylj-7-fluoro-6-[5([2. (methanesulIphonyflethyl jam ino}methyl)-2-fu ryl]-4-qu inazol inin e; N-[4-(3-FI uoro-benzyloxy)-3-chlorophenyl]-7-fluoro-6{5-({[2 (methanesul phonyl)ethyl]a minolmethyl)-2-furyl]-4-qu inazol inamine N-[4-Benzyloxy-3-bromophe nyl]-7-fluo ro-6-[5-({[2 (methanesulphonyl)ethyl]aminolmethy)-2-furyl].4-quinazolinarnjne N -[4-(3-Fl uoro-benzyloxyy3-bromop hen ylp7-fluo ro-6[5-([2-. (methanesulphonyI)ethylqaminolmethyI>2furyI]A4quinazolinamjne N-[4-Benzyloxy-3-fluorophenyl-7-fluoro6rs.{[2. (metha nesul pho ny)ethylaminolmethyl)-2fu ryJA..qu in azo ijna mine N-[4-(3-Fluoro-benzyloxy)-3-fl uomophenyl]-1-fiuoro-6-[5-({ [2 (metha nesulphonyl)ethylam ino}methyl)p2tu ryl]A4qu inazopina mine List 8 O: docsPateritsMARSPEGSpG341 Oau, DOG 11 N-[4-(Benzyloxy)-3-chloropheny]-7-methoxy-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluom-benzyloxy)-3-chlorophenyl]-7-methoxy-6-2[2 (methanesulphonyl)ethylamino}methyl)-1,3-thiazol-4-y]-4-quinazolinamine; N-[4-Benzyloxy-3-bromophenyl]-7-methoxy-6-[2-({[2 (methanesulphonyl)ethylamino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-bromophenyl]-7-methoxy-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yJ-4-quinazolinamine; N-[4-Benzyloxy-3-fluorophenyl]-7-methoxy-6-[2-({[2 (metha nesulphonyl)ethyl]am ino}methyl)-1,3-th iazol-4-yl-4-qu inazoli namine; N-[4-(3-Fluoro-benzyloxy)-3-fluorophenyl]-7-methoxy-6-[2-({[2 (methanesu lphonyl)ethyl]amino)methyl)- 1,3-thiazol-4-yl]-4-qu inazolinamine; List 9 N-[4-(Benzyloxy)-3-chlorophenyl]-7-fluoro-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-ylJ-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-chlorophenyl]-7-fluoro-6-[2-{[2 (metha nesulphonyl)ethyl]amino}methyl)-1,3-th iazol-4-ylJ-4-qu inazoli namine; N-[4-Benzyloxy-3-bromophenyl-7-fluoro-6-[2-({[2 (methanesulphonyl)ethyljamino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-bromophenyl]-7-fluoro-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yi]-4-quinazolinamine; N-[4-Benzyloxy-3-fluorophenyl]-7-fluoro-6-[2-({[2 (methanesulphonyl)ethylamino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-fluorophenyl]-7-fluoro-6-[2-({[2 (methanesu I phonyl)ethyla mino}methyl )- 1, 3-thiazol-4-y]-4-qu inazol ina mine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof Particularly preferred compounds of the present invention include: (4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesu Iphonyl-ethylamino)methyl) furan-2-yI)-pyrido[3,4-d]pyrimidin-4-yl)-amine; 0:docsPatentsMARkSPECSPG3416au.DOC 12 N-{4-[(3-Fluorbenzyl)oxyjphenyl}-6-[5-({[2-(methanesulphonyl)ethyl]aminolmethyl) 2 -furyl]-4-quinazolinamine;
N-{
3 -Fluoro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2 (methanesulphonyl)ethyljamino}methyl)-2-furylj-4-quinazolinamine;
N-{
3 -Fluoro-4-[(3-fluorobenzyl)oxylphenyl)-6-[2-({[ 2 (methanesulphony)ethyl]amino)methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-(3-Fluoro-4-benzyloxyphenyl)-6-[5-({[2-(methanesulphonyl)ethyl]aminomethyl)-4 furyl]-4-quinazolinamine; N-(3-Chloro-4-benzyloxyphenyl)-6-[2-({{2-(methanesulphonyl)ethyllamino methyl)-4 furyl]-4-quinazolinamine;
N-{
3 -Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2 (methanesulphonyl)ethy]amino}methyl)-2-furyl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof. Certain compounds of formula (1) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are included within the scope of the present invention. Likewise, it is understood that compounds of formula (1) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention. Salts of the compounds of the present invention may comprise acid addition salts derived from a nitrogen in the compound of formula (1). The therapeutic activity resides in the moiety derived from the compound of the invention as defined herein and the identity of the other component is of less importance although for therapeutic and prophylactic purposes it is, preferably, pharmaceutically acceptable to the patient. Examples of pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p-toluenesulphonic, acids. O:docsPatentsMARSPECSPG3416au.
DOC
13 According to a further aspect of the present invention there is provided a process for the preparation of a compound of formula (1) as defined above which comprises the steps: (a) the reaction of a compound of formula (II) L N"9N NI) V. N H wherein Y' is CL' and V' is N; or Y' is CL' and V is CR 2 wherein R 2 is as defined above and L and L' are suitable leaving groups, with a compound of formula (Ill)
H
2 N R3 wherein R3 and R 4 are as defined above, to prepare a compound of formula (IV) R3 R4 HN H (IV) and subsequently (b) reaction with appropriate reagent(s) to substitute the group R by replacement of the leaving group L'; and, if desired, (c) subsequently converting the compound of formula (I) thereby obtained into another compound of formula (1) by means of appropriate reagents. O:docsPatentsMARSPECSPG3416au,
DOC
14 Alternatively, the compound of formula (11) as defined above is reacted with the appropriate reagents to substitute the group R' by replacement of the leaving group L' and then the product thereby obtained (of formula (V) below) is reacted with the compound of formula (111) as defined above, followed, if desired, by conversion of the compound of formula (I) thereby obtained into another compound of formula (1). In a variant of this alternative the compound of formula (V) L 11M V A 5 N H wherein Y, V and L are as defined above, may be prepared by the reaction of a compound of formula (VI) 0 Y.NH (VI) 11 N H wherein V' and Y' are as defined above, with appropriate reagents to substitute the group R' for the leaving group L' to prepare a compound of formula (VII) 0 Yt NH (VII) N H and subsequent reaction to incorporate the leaving group L. For example, a chloro leaving group can be incorporated by reaction of a corresponding 3,4 dihydropyrimidone with carbon tetrachloride/triphenylphosphine in an appropriate solvent. The group R1 may, therefore, be substituted onto the basic ring system by replacement of a suitable leaving group. This may, for example, be carded out by reaction of the corresponding aryl or heteroaryl stannane derivative with the O:docsPatentsMARSPECSPG3416au.DOC 15 corresponding compound of formula (IV) carrying the leaving group L' in the appropriate position on the ring. According to a further aspect of the present invention there is provided a process for 5 the preparation of a compound of formula (1) as defined above which comprises the steps: (a) reacting a compound of formula (IV) as defined above with appropriate reagent(s) to prepare a compound of formula (VIII) HN N (Vill) N H wherein R 3 and R4 are as defined above; Y" is CT and V" is N; or Y" is CT and V" is CR 2 wherein R 2 is as defined above and T is an appropriately functionalised group; and (b) subsequently converting the group T into the group R' by means of appropriate reagent(s); and, if desired, (c) subsequently converting the compound of formula (1) thereby obtained into another compound of formula (1) by means of appropriate reagents. In one alternative, the group T would represent a group Ar as defined above carrying a formyl group (CHO). Where T represents a group Ar carrying a formyl group the compound (of formula (Villa)) may be suitably prepared from the corresponding dioxolanyl substituted compound (of formula (Villb)), for example by acid hydrolysis. The dioxolanyl substituted compound may be prepared by reaction of a compound of formula (IV) with an appropriate reagent to substitute the relevant leaving group with the substituent carrying the dioxolanyl ring. This reagent could, for example, be an appropriate heteroaryl stannane derivative. O:docsPatentsMARSPECSPG3416au.DOC 16 Therefore a suitable process may comprise reaction of a compound of formula (Villa) in which T is a group Ar carrying a formyl substituent (i.e. a -CHO group) with a compound of formula CH 3
SO
2
CH
2
CH
2
NH
2 . The reaction preferably involves a reductive amination by means of an appropriate reducing agent, for example sodium triacetoxyborohydride. Alternatively, another suitable process may comprise oxidation of a compound of formula (VllIc) in which T is a group Ar carrying a substituent of formula
CH
3
SCH
2
CH
2
NHCH
2 or CH 3
SOCH
2
CH
2
NHCH
2 . Suitable methods for the oxidation to the desired compound of formula (1) will be well known to the person skilled in the art but include, for example, reaction with an organic peroxide, such as peracetic acid or metachlorobenzoic acid, or reaction with an inorganic oxidising agent, such as OXONE*. The compound of formula (VIlic) in which T is a group Ar carrying a substituent of formula CH3SCH 2
CH
2
NHCH
2 or CH 3
SOCH
2
CH
2
NHCH
2 may be prepared by an analogous reaction to that described above, namely reaction of a compound of formula (Villa) in which T is a group Ar carrying a formyl substituent (i.e. a -CHO group) with a compound of formula CH 3
SCH
2
CH
2
NH
2 or
CH
3
SOCH
2
CH
2
NH
2 respectively. Alternatively, an analogous scheme to those described above could be used wherein the substitution of the group R 1 onto the basic ring system occurs prior to the coupling reaction with the compound of formula (111). According to a further alternative process the group T is converted into the group R by a de novo synthesis of a substituted heterocyclic system using appropriate agents. Such a process would involve standard synthetic methodology known to the person skilled in the art for building up the heterocylic ring system. For example, T could represent a haloketone group as shown in the compound of formula (IX) in scheme I below which, when coupled with an appropriate N protected thioamide [compound of formula (XI) in scheme 2], would result in the formation of an N-protected amino-substituted thiazole system of formula (X). 0:docsPatentsMARSPECSPG3416au.DOC 17 Scheme I outlines, for example, the synthesis of derivatives carrying a substituted thiazole ring as an R 1 substituent: HN HNU alkyltin /Pd catalyst Br 2 or NBS a N O Y N y1
N
9 N (IVa) (IX) PU 0 HN US HN Br thiomide N N IN NN ~ N' 0C, DMF V (Xa) (X b) "U S HN 2M NaOH/Me (1:1) hydrolysis N Y N (I) U= Scheme I wherein Hal' is a halogen atom (preferably iodo), and P' in the compound of formula (XI) is a suitable protecting group, such as trifluorocarbonyl. O:WocsPatentsMARSPECSPG3416au.DOC 18 An appropriately substituted thioamide coupling reagent, suitable for preparation of a thiazole ring system, may be prepared according to Scheme 2: CI CN O CF NaHCO, ,MeCN TEA or NMM , o"C SX 2 reflux NA CN TFAA sA N ,CN (XIlI) (XIV) O CF 3 o CFs Oxone or MCPBA TEA in DMF, H S (g) NH 0 "C N N (XV) (XVIa) Scheme 2 Wherein in scheme 2 the trifluorocarbonyl protecting group in the compounds of formula (XIV), (XV) and (XVIa) is equivalent to the group P' in scheme 1. Alternatively, an analogous scheme to those described above could be used wherein the substitution of the group R' onto the basic ring system occurs prior to the coupling reaction with the compound of formula(Ill). Other substituted thioamides are prepared using analogous processes to that shown above. In general, the group R2 will be present as a substituent in the basic ring system prior to the introduction of the group R' or the anilino group. Where R2 is other than hydrogen it may in certain circumstances be necessary to protect the group prior to performing the reaction steps to introduce the R' and anilino substituents. Particular mention should be made of the situation where R 2 is hydroxy; suitable protecting groups to ensure non-interference with the subsequent reaction steps include the 2 O:docsPatentsMARSPECSPG3416au.DOC 19 methoxyethoxymethyl ether (MEM) group or a bulky silyl protecting group such as tert-butyldiphenylsilyl (TBDPS). Suitable protecting groups, methods for their introduction and methods for their removal would be well known to the person skilled in the art. For a description of protecting groups and their use see T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2nd edn., John Wiley & Sons, New York, 1991. Suitable leaving groups for L and L' will be well known to those skilled in the art and include, for example, halo such as fluoro, chloro, bromo and iodo; sulphonyloxy groups such as methanesulphonyloxy and toluene-p-sulphonyloxy; alkoxy groups; and triflate. The coupling reaction referred to above with the compound of formula (1ll) is conveniently carried out in the presence of a suitable inert solvent, for example a
C
1
.
4 alkanol, such as isopropanol, a halogenated hydrocarbon, an ether, an aromatic hydrocarbon or a dipolar aprotic solvent such as acetone, acetonitrile or DMSO at a non-extreme temperature, for example from 0 to 150*C, suitably 10 to 120*C, preferably 50 to 100oC. Optionally, the reaction is carried out in the presence of a base. Examples of suitable bases include an organic. amine such as triethylamine, or an alkaline earth metal carbonate, hydride or hydroxide, such as sodium or potassium carbonate, hydride or hydroxide. The compound of formula (1) may be obtained from this process in the form of a salt with the acid HL, wherein L is as hereinbefore defined, or as the free base by treating the salt with a base as hereinbefore defined. The compounds of formulae (1l) and (111) as defined above, the reagents to substitute the group R 1 , and the reagent(s) to convert the group T into the group R1 are either readily available or can be readily synthesised by those skilled in the art using conventional methods of organic synthesis. O:docsPatentsMARSPECSPG3416auDOC 20 As indicated above, the compound of formula (1) prepared may be converted to another compound of formula (1) by chemical transformation of the appropriate substituent or substituents using appropriate chemical methods (see for example, J.March "Advanced Organic Chemistry", Edition Ill, Wiley Interscience, 1985). Similar chemical transformations may also be used to convert any relevant intermediate compound to another intermediate compound prior to the final reaction to prepare a compound of formula (1); this would thus include their use to convert one compound of formula (111) to a further compound of formula (1ll) prior to any subsequent reaction. The compounds of formula (1) and salts thereof have anticancer activity as demonstrated hereinafter by their inhibition of the protein tyrosine kinase c-erbB-2, c-erbB-4 and/or EGF-R enzymes and their effect on selected cell lines whose growth is dependent on c-erbB-2 or EGF-r tyrosine kinase activity. The present invention thus also provides compounds of formula (1) and pharmaceutically acceptable salts or solvates thereof for use in medical therapy, and particularly in the treatment of disorders mediated by protein tyrosine kinase activity such as human malignancies and the other disorders mentioned above. The compounds of the present invention are especially useful for the treatment of disorders caused by aberrant c-erbB-2 and/or EGF-r activity such as breast, ovarian, gastric, pancreatic, non-small cell lung, bladder, head and neck cancers, and psoriasis. A further aspect of the invention provides a method of treatment of a human or animal subject suffering from a disorder mediated by protein tyrosine kinase activity, including susceptible malignancies, which comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. A further aspect of the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, in therapy. O:docsPatentsMARSPECSPG3416au.
DOC
21 A further aspect of the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of cancer and malignant tumours. 5 A further aspect of the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of psoriasis. Whilst it is possible for the compounds, salts or solvates of the present invention to ) be administered as the new chemical, it is preferred to present them in the form of a pharmaceutical formulation. According to a further feature of the present invention there is provided a pharmaceutical formulation comprising at least one compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents or excipients. Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit may contain for example 0.5mg to 1g, preferably 70mg to 700mg, more preferably 5mg to 100mg of a compound of the formula (I) depending on the condition being treated, the route of administration and the age, weight and condition of the patient. Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s). Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in water liquid emulsions or water-in-oil liquid emulsions. O:docsPatentsMARSPECSPG3416au.
DOC
22 Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986). Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For treatments of the eye or other external tissues, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base. Pharmaceutical formulations adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent. Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes. Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas. Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient. O:docSP2tentsMARSPECSPG3416au.DOC 23 Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulizers or insuffiators. Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations. Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents. The animal requiring treatment with a compound, salt or solvate of the present invention is usually a mammal, such as a human being. A therapeutically effective amount of a compound, salt or solvate of the present invention will depend upon. a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian However, an effective amount of a compound of the present invention for the treatment of neoplastic O:doCsPatentsMARSPECSPG3 4 16au.DOC 24 growth, for example colon or breast carcinoma, will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of I to 10 mg/kg body weight per day. Thus, for a 70kg adult mammal, the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt or solvate of the present invention may be determined as a proportion of the effective amount of the compound per se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above. The compounds of the present invention and their salts and solvates may be employed alone or in combination with other therapeutic agents for the treatment of the above-mentioned conditions. In particular, in anti-cancer therapy, combination with other chemotherapeutic, hormonal or antibody agents is envisaged. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (1) or a pharmaceutically acceptable salt or solvate thereof and at least one other pharmaceutically active agent. - The compound(s) of formula (1) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order. The amounts of the compound(s) of formula (1) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. Certain embodiments of the present invention will now be illustrated by way of example only. The physical data given for the compounds exemplified is consistent with the assigned structure of those compounds. "H NMR spectra were obtained at 500MHz on a Bruker AMX500 spectrophotometer, on a Bruker spectrophotometer at 300MHz, on a Bruker AC250 or Bruker AM250 spectrophotometer at 250MHz and on a Varian Unity Plus NMR spectrophotometer at 300 or 400 MHz. J values are given in Hz. Mass spectra were obtained on one of the following machines: VG Micromass Platform (electrospray positive or negative), HP5989A Engine (thermospray positive) or Finnigan-MAT LCQ (ion trap) mass Q:docsPatentsMARSPEcSPG3416au.DOC 25 spectrometer. Analytical thin layer chromatography (tic) was used to verify the purity of some intermediates which could not be isolated or which were too unstable for full characterisation, and to follow the progess of reactions. Unless otherwise stated, this was done using silica gel (Merck Silica Gel 60 F254). Unless otherwise stated, column chromatography for the purification of some compounds used Merck Silica gel 60 (Art. 1.09385, 230-400 mesh), and the stated solvent system under pressure. Petrol refers to petroleum ether, either the fraction boiling at 40-600C, or at 60 800C. Ether refers to diethylether. DMSO refers to dimethylsulphoxide. THF refers to tetrahydrofuran. HPLC refers to high pressure liquid chromatography. NMM refers to N-methylmorpholine Useful preparative techniques are described in W096/09294, W097/03069, W097/13771, W095/19774, W096/40142 and W097/30034; also described in these publications are appropriate intermediate compounds other than those detailed below. Preparation processes specified in the prior art or in the experimental details below for compounds with a particular basic ring system (1) to (6) above may be suitably adapted for others of these basic ring systems. General Procedures (A) Reaction of an amine with a bicyclic species containing a 4-chloropyrimidine or 4-chloropyridine ring The optionally substituted bicyclic species and the specified amine were mixed in an appropriate solvent (typically acetonitrile unless otherwise specified, although ethanol, 2-propanol or DMSO may also be used), and heated to reflux. When the reaction was complete (as judged by tic), the reaction mixture was allowed to cool. The resulting suspension was diluted, e.g. with acetone, and the solid collected by filtration, washing e.g. with excess acetone, and dried at 60*C in vacuo, giving the product as the hydrochloride salt. If the free base was required O:docsPatentsMARSPECSPG3416au.DOC 26 (e.g. for further reaction), this was obtained by treatment with a base e.g. triethylamine; purification by chromatography was then performed if required. (B) Reaction of a product from Procedure (A) with a heteroaryl tin reagent A stirred mixture of the product from Procedure (A), (containing a suitable leaving group such as chloro, bromo, iodo or triflate), a heteroaryl stannane and a suitable palladium catalyst, such as bis(triphenylphosphine)palladium (II) chloride or 1,4-bis(diphenylphosphino)butane palladium (11) chloride (prepared as described in C.E. Housecroft et. al., Inorg. Chem., (1991), 30(1), 125-130), together with other appropriate additives (such as diisopropylethylamine or lithium chloride), were heated at reflux in dry dioxane or another suitable solvent (e.g. DMF) under nitrogen until the reaction was complete. The resulting mixture was generally purified by chromatography on silica. (C) Removal of a 1,3-dioxolan-2-yl protecting group to liberate an aldehyde The compound containing the 1,3-dioxolan-2-yl group was suspended in an appropriate solvent, e.g.THF and treated with hydrochloric acid, either as an aqueous solution (e.g. 2N) or as a solution in dioxane (e.g. 4 molar) and stirred at ambient temperature until the reaction was judged complete (e.g. by tic or LC/MS analysis). Generally the mixture was diluted with water, and the resulting precipitate was collected by filtration, washed with water and dried to give the aldehyde. (D) Reaction of an aldehyde with an amine by reductive amination An aldehyde (such as the product of General Procedure C) and the required primary or secondary amine were stirred together in a suitable solvent (such as dichloromethane) containing glacial acetic acid ( 4A molecular sieves may also be present) for ca. 1h. A suitable reducing agent, such as sodium (triacetoxy) borohydride was then added and stirring continued under nitrogen until the reaction was complete (as judged by hplc or tic). The resulting mixture was washed with an aqueous basic solution (e.g. sodium or potassium carbonate) and extracted with a suitable solvent, e.g. dichloromethane. The dried organic phase was evaporated and the residue purified either by column chromatography or by Bond ElutTM cartridge. If desired, the isolated material was 0:docsPatentswARSPECSPG3416au.DOC 27 then converted into the hydrochloride salt e.g. by treatment with ethereal hydrogen chloride. (E) Reaction sequence to prepare appropriately substituted thioamides E-1 Reaction of an aminosulfide with chloroacetonitrile To a stirred mixture of an aminosulfide and a suitable base such as sodium bicarbonate or sodium carbonate in an appropriate solvent (typically acetonitrile, although DMF or dioxane can be used) was added chloroacetonitrile dropwise. The resulting mixture was heated to reflux until the reaction was complete. The solid was filtered and the filtrate was concentrated to provide the corresponding aminonitrile. E-2 Trifluoroacetamide protection of an aminonitrile A solution of the aminonitrile (such as the product of general procedure A) and an amine base, such as triethylamine or NMM in a suitable solvent (e.g. dichloromethane), was cooled to 0*C and trifluoroacetic anhydride was added dropwise. The resulting mixture was stirred at room temperature until the reaction was complete. Water was added and the mixture was extracted with a suitable solvent (e.g. dichloromethane), the organic layer was dried over anhydrous magnesium sulfate and concentrated. The crude product was purified by column chromatography to provide the corresponding trifluoroacetamide. E-3 Oxidation of a cyanosulfide To a stirred solution of a sulfide (such as the product of general procedure El) in a suitable solvent (typically methanol/water (2:1), although dichloromethane can be used) cooled to O*C was added an oxidizing agent (typically oxone, although MCPBA can be used). The resulting mixture was stirred at room temperature until the reaction was complete. The reaction was concentrated to remove any organic solvents, diluted with water, and extracted with an appropriate solvent (e.g. dichloromethane). The organic layer was dried and concentrated to provide the corresponding cyanosulfone. E-4 Preparation of thioamides To a solution of a cyanosulfone (such as the product of general procedure E-3 ) and an organic base (e.g. triethylamine) in THF was added hydrogen sulfide gas. The O:docsPatentsMARSPECSPG3416au.DOC 28 resulting mixture was stirred at room temperature until the reaction was complete. The mixture was concentrated and triturated with hexane to provide thioamide. (F) Reaction sequence to prepare an optionally substituted thiazole F-1 Reaction of a vinvIstannane with a product from Procedure (A) A stirred mixture of the optionally substituted bicyclic 4-anilinopyrimidine species, tributyl(I-ethoxyvinyl)stannane (1 to 5 molar equivalents), and a suitable palladium catalyst (0.03 to 0.1 molar equivalents), such as bis(triphenylphosphine) palladium (i) chloride or tetrakis(triphenylphosphine) palladium (0) was heated at reflux in an appropriate solvent (typically acetonitrile, although DMF or dioxane can be used) until the reaction was complete. The resulting mixture" was concentrated and generally purified by trituration with diethyl ether to provide the corresponding bicyclic pyrimidine vinyl ether. F-2 Reaction of a product from Procedure (F-1) with a bromination reagent A bicyclic pyrimidine vinyl ether (such as the product of general procedure F-1) and I equivalent of a bromination reagent, such as N-bromosuccinimide or bromine, were stirred at 0"C in a- suitable solvent (typically 10% aqueous THF or dichloromethane) until the reaction was complete. The resulting mixture was dried over anhydrous magnesium sulfate and concentrated, or in the case of bromine the solid was filtered, to provide the corresponding a-bromoketone. F-3 Reaction of a product from procedure (F-2) with a product from Procedure (E-4) A stirred mixture of an a-bromoketone (such as the product of general procedure F 2) and thioamide from Procedure E-4 in a 1:1 molar ratio was heated to 70-1 00*C in an appropriate solvent (typically DMF, although acetonitrile and THF can be used) until the reaction was complete. The resulting mixture was washed with an aqueous basic solution (e.g. sodium carbonate) and extracted with a suitable solvent, e.g. ethyl acetate. The dried organic layer was concentrated and the residue was purified by column chromatography to provide the corresponding trifluoroacetamide aminothiazole. F-4 Removal of a trifluoroacetamide protecting group to liberate an aminothiazole O:docsPatentsMARSPECSPG3416au.
DOC
29 A mixture of a trifluoroacetamide protected aminothiazole (such as the product of general procedure F-3) in 2M NaOH/methanol (1:1) was stirred at room temperature until the reaction was complete. The mixture was concentrated, poured into water and extracted with an appropriate solvent e.g. 10% MeOH/dichloromethane. The dried organic layer was concentrated, then dissolved in ethyl acetate/MeOH (1:1) and treated with 4M HCI/dioxane. The resulting solid was filtered to provide the corresponding amine hydrochloride salt. Synthesis of Intermediates N-5-[N-ted-Butoxvcarbonyl)aminol-2-chloropyridins A stirred solution of 6-chloronicotinic acid (47.3g), diphenylphosphoryl azide (89.6g) and triethylamine (46ml) in t-butanol (240ml) were heated under reflux under nitrogen for 2.5 hours. The solution was cooled and concentrated in vacuo. The syrupy residue was poured into 3 litres of a rapidly stirred solution of 0.33N aqueous sodium carbonate. The precipitate was stirred for one hour and filtered. The solid was washed with water and dried in vacuo at 70C to give the title compound (62g) as a pale brown solid; m.p. 144-146*C; 8H [ 2 H6]-DMSO 8.25(1H,d), 7.95 (1H, bd), 7.25 (1H, d), 6.65(1 H, bs), 1.51 (9H,s); m/z (M + 1) 229. This material may subsequently be carried forward to the appropriately substituted pyridopyrimidine intermediate according to the procedures as described in W095/19774, J. Med. Chem., 1996, 39, pp 1823-1835, and J. Chem. Soc., Perkin Trans. 1, 1996, pp 2221-2226. Specific compounds made by such procedures include 6-ch loro-pyrido[3,4-djpyri mid i n-4-one and 4,6-dichloro-pyrido[3,4 dipyrimidine. 2-Amino-4-fluoro-5-iodo-benzoic acid To a vigorously stirred solution of dichloromethane (700 ml), methanol (320 ml), and 2-amino-4-fluoro-benzoic acid (33.35 grams, 215 mmoles) was added solid sodium hydrogencarbonate (110 grams, 1.31 moles) followed by portion addition of benzyltrimethyl ammonium dichloroiodate (82.5 grams, 237 mmoles). The mixture was allowed to stir for 48 hours. The mixture was filtered to remove the insolubles. The remaining solid residue was washed with 200 ml of dichloromethane. The filtrate was concentrated and redissolved in a one to one o:docsPatentsMARSPECSPG3416au.DOC 30 mixture of ethyl acetate (1 litre) and a 0.2 N solution of sodium hydroxide (1 litre), added to a 2 litre separatory funnel and extracted. The organic layer was washed with an additional 200 ml of water. The aqueous layers were combined and acidified with 2N hydrochloric acid. The resulting precipitate was collected 5 by suction filtration, washed with water and dried under vacuum at 600C to yield 46.5 grams (77%) of the title compound. 'H NMR (400 MHz, DMSO-d 6 ) 6: 8.04(d, IH), 7.1(s, broad, 2H), 6.63(d, IH). ESI-MS m/z 280 (M-1). 4-Fluoro-5-iodo-isatoic anhydride P Anhydrous dioxane (0.5 litres), 2-amino-4-fluoro-5-iodo-benzoic acid (46 grams, 164 mmoles), and trichloromethylchloroformate (97.4 grams, 492 mmoles) were added to a one litre one neck flask equipped with a magnetic stir bar and reflux condenser. The solution was placed under anhydrous nitrogen, stirred and heated to reflux for 16 hours. The reaction mixture was allowed to cool and was poured into one litre of hexanes. The solid was collected by suction filtration, washed with an additional 0.5 litres of hexanes, and dried under vacuum at room temperature to yield 45.5 grams (90%) of the title compound. 'H NMR (400 MHz, DMSO-d 6 ) 8: 11.86(s, 1H), 8.24(d, IH), 6.84(d, IH). ESI-MS m/z 308 (M+1). 4-Chloro-6-bromoguinazoline and 4-Chloro-6-iodoquinazoline were prepared as described in WO 96/09294. 4-Hydroxy-6-iodo-7-fluoroquinazoline Dimethylformamide (0.5 litres), 4-fluoro-5-iodo-isatoic anhydride (45 grams, 147 mmoles), and formamidine acetate (45.92 grams, 441 mmoles), were combined in a one litre one-neck flask fitted with a magnetic stir bar. The mixture was placed under anhydrous nitrogen and heated at 110 C for 6 hours. The mixture was allowed to cool, followed by concentrating the reaction mixture to one third its original volume on the rotary evaporator. The resulting mixture was poured onto 3 litres of ice water. The resulting precipitated solid was collected by suction filtration. The solid was washed with an additional one litre of distilled water. The resulting solid was dried under vacuum at 70*C to yield 38.9 grams (91%) of the title compound. 1 H NMR (400 MHz, DMSO-d 6 ) 8: 12.43(s, IH), 8.46(d, 1H), 8.12(s, 1H), 7.49(d, 1H). ESI-MS m/z 291(M+1). O:docsPatentsMARSPECSPG3416au.DOC 31 4-Chloro-6-iodo-7-fluoro-qiuinazoline hydrochloride Thionyl chloride (0.6 litres), 4-hydroxy-6-iodo-7-fluoro-quinazoline (36 grams, 124 mmoles), and dimethylformamide (6 ml) were combined in a one litre one-neck flask fitted with a magnetic stir bar. The mixture was placed under anhydrous nitrogen and heated to a gentle reflux for 24 hours. The mixture was allowed to cool, followed by concentrating the reaction mixture to a thick yellowish residue. To this residue was added dichloromethane (0.1 litre) and toluene (0.1 litre). The mixture was concentrated to dryness. This procedure was repeated two additional times. To the resulting solid was added 0.5 litres of dry dichloromethane and the mixture was stirred for one hour. The mixture was filtered and the remaining solids were washed with minimal dichloromethane. The dichoromethane filtrates were combined, concentrated to a solid, and dried under vacuum at room temperature to yield 28.6 grams (67%) of the title compound. 1H NMR (400 MHz, CDCI 3 -d1) 8: 9.03(s, 1 H), 8.76(d, 1 H), 7.69(d, 1 H). ESI-MS m/z 309(M+1). 2-Bromo4-(1,3-dioxolan-2-yl)thiazole 2-Bromothiazole-4-carbaldehyde (6.56g,34.17mmol) [A.T. Ung, S.G.Pyne/ Tetrahedron: Asymmetry 9 (1998) 1395-1407]and ethylene glycol (5.72m, 102.5 mmol) were heated under reflux in toluene (50m) ,with a Dean and Stark trap fitted, for 18hr. The product was concentrated and purified by column chromatography (15% ethyl acetate /hexane) to give the product as a yellow solid (6.03g); m/z 236,238. 4-(1,3-Dioxolan-2-yl)-5-(tributylstannyl)thiazole 2-Bromo-4-(1,3-dioxolan-2-yl) thiazole (6.4 g ,27.14 mmol) was stirred at -780 C in dry THF (38ml).1.6M n butyl lithium in hexane (18.6ml, 29.78 mmol) was added dropwise under nitrogen. After 30min at this temperature, tributyl tin chloride (7.35ml,27.14 mmol) was added dropwise. The reaction was allowed to warm to 0* and water (20ml) was added. The product was extracted into ether (3x100ml). The combined organic extracts were dried (MgSO 4 ) and evaporated. The residue was triturated with isohexane (3x100ml) and the mother liquors were decanted, combined and concentrated to give a brown oil (11.88g); m/z 444 450. O:docsPatentsMARSPECSPG3416au.DOC 32 Substituted anilines were in general prepared by analogous methods to those outlined in WO 96/09294 and/or as follows: Step 1: Preparation of the precursor nitro-compounds 4-Nitrophenol (or an appropriate substituted analogue, such as 3-chloro-4 nitrophenol) was treated with a base such as potassium carbonate or sodium hydroxide in an appropriate solvent, such as acetone or acetonitrile. The appropriate aryl or heteroaryl halide was added and the reaction mixture heated or stirred at room temperature overnight. Purification A: Most of the acetonitrile was removed in vacuo, and the residue was partitioned between water and dichloromethane. The aqueous layer was extracted with further dichloromethane (x 2), and the combined dichloromethane layers were concentrated in vacuo. Purification B: removal of insoluble material by filtration, followed by concentration of the reaction mixture in vacuo, and chromatography on silica. Step 2: Reduction to the corresponding aniline The precursor nitro compound was reduced by catalytic hydrogenation at atmospheric pressure using 5% Pt/carbon, in a suitable solvent (eg ethanol, THF, or mixtures thereof to promote solubility). When reduction was complete, the mixture was filtered through HarborliteTM, washing with excess solvent, and the resulting solution concentrated in vacuo to give the desired aniline. In some cases, the anilines were acidified with HCI (e.g. in a solution in dioxane) to give the corresponding hydrochloride salt. Anilines prepared by such methods include: 4-(3-Fluorobenzyloxy)aniline; m/z (M+1)* 218 3 -Chloro-4-(2-fluorobenzyloxy)aniline; m/z (M+1)* 252 3-Chloro-4-(3-fluorobenzyloxy)aniline; m/z (M+1)* 252 3 -Chloro-4-(4-fluorobenzyloxy)aniline; m/z (M+1)* 252 4-Benzyloxy-3-chloroaniline; m/z (M+1)* 234 and, in appropriate cases, their hydrochloride salts. 0:doGsPatentsMARSPECSiPG3416au.DOC 33 4-(Trbutylstannyl)thiazole-2-carbaldehyde 4-Bromo-2-(tributylstannyl)thiazole (T.R. Kelly and F. Lang, Tetrahedron Lett., 36, 9293, (1995)) (15.0g) was dissolved in THF (150ml) under a nitrogen atmosphere, cooled to -85 0 C and treated with t-BuLi (1.7M, in pentane, 43ml). The mixture was stirred at -85 0 C for 30min, and then N-formylmorpholine (8.4g) was added by syringe. After further stirring at -85*C for 10min the mixture was allowed to warm to room temperature. Water (200ml) was added and the mixture was extracted with diethyl ether (4 x 100ml). The combined ethereal extracts were washed with water, dried (NaSO4), and concentrated in vacuo. Chromatography on silica, eluting with 10%ether/i-hexane, gave the title compound as a yellow oil; 8H [ 2
H
6 ]DMSO 10.03 (1H,s), 8.29 (1H,s), 1.55(6H,q), 1.21-1.37 (6H,m), 1.09-1.20 (6H,m), 0.85 (9H,t). 6-lodo-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-quinazolin-4y)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3 chlorophenyl)amine and 4-chloro-6-iodo-quinazoline. 1H NMR (DMSO-d6) 9.83 (s, IH); 8.92 (s, IH); 8.58 (s, IH); 8.09 (d, 1H); 8.00 (d, 1H); 7.61 (d, 1H); 7.52 (d, IH); 7.44 (m, 1H); 7.20-7.33 (m, 3H); 7.15 (m, 1H); 5.21 (s, 2H); MS m/z 506 (M+1). 6-lodo-(4-(3-fluorobenzy1oxy)-3-fluorophenyI)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3 fluorophenyl)amine and 4-chloro-6-iodo-quinazoline. 1H NMR (DMSO-d6) 9.83 (s, 1H); 8.92 (s, 1H); 8.57 (s, 11H); 8.08 (d, 1H); 7.85 (d, 1H); 7.53 (d, 1H); 7.50 (d, 1H); 7.43 (m, 1H); 7.30-7.20 (m, 3H); 7.15 (m, IH); 5.20 (s, 2H); MS m/z 490 (M+1). 6 -lodo-(4-(3-fluorobenzyloxy)-3-methoxyphenvi)-quinazolin-4yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-3 methoxyphenyf)amine and 4-chloro-6-iodo-quinazoline. 1 H NMR 400 MHz (DMSO d6) 11.29 (bs, IHO; 9.14 (s,1H); 8.87 (s,1H); 8.32 (d,1H); 7.62 (d,IH); 7.42 (m,1H); 7.34 (d,1H); 7.29-7.22 (m,3H); 7.18-7.08 (m,2H); 5.15 (s,2H); 3.80 (s,3H); MS m/z 502 (M+1) 6-lodo-(4-benzylox-3-fluorophenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from 4-benzyloxy)-3-fluorophenylamine and 4 chloro-6-iodo-quinazoline. 'H NMR (DMSO-d6) 9.82 (s, 1H); 8.93 (s, 1H); 8.57 (s, O:docsPatentsMARSPECSPG3416auiDOC 34 1H); 8.09 (d, 1H); 7.84 (d, 1H); 7.51 (m, 2H); 7.44 (d, 2H); 7.37 (m, 2H); 7.33 (m, 1H); 7.24 (m, 1 H); 5.18 (s, 2H); MS m/z 472 (M+1) 6 -lodo-(4-(3-fluorobenzvloxy)-phenyl)-quinazolin-4-yl)amine Prepared according to Procedure A from (4-(3-fluorobenzyloxy)-phenyl)amine and 4 chloro-6-iodo-quinazoline. H NMR (DMSO-d6) 9.77 (s, IH); 8.92 (s, 1H); 8.50 (s, 1H); 8.06 (d, 1H); 7.66 (d, 2H); 7.50 (d, 1H); 7.42 (m, 1H); 7.30-7.25 (m, 2H); 7.14 (m, 1H); 7.03 (d, 2H); 5.13 (s, 2H); MS m/z 472 (M+1) 6-(5-(1,3-Dioxolan-2-yl-furan-2-yl)-7-methoxy-guinazolin-4-yl-(4 benzenesulphonyl)phenvl-amine Prepared according to Procedure B from 4-(4-benzenesulphonyl)phenyl-7 methoxy-quinazolin-4-yl-amine and 5-(1,3-d ioxolan-2-yl)-2-(tributylstan nyl)fu ran. S11 NMR (400 MHz, DMSO-de) 10.36(s, 1H), 8.74(s, 1H), 8.58(s, 1H), 8.10(d, 2H), 7.93(m, 4H), 7.62(m, 3H), 7.32(s, 1H), 7.04(d, 1H), 6.68(d, 1H), 5.99(s, 1H), 4.09(m, 2H), 4.04(s, 3H), 3.95(m, 2H). ESI-MS m/z 530(M+1). (6-Chloropyrido[3,4-dlrvdmidin-4-vl)-(4-(3-fluorobenzvloxy)-phenyl)-amine 4,6-Dichloro-pyrido[3,4-d]pyrimidine (1g) and 4-(3-fluorobenzyloxy)aniline (1.08g) in acetonitrile (70ml) were reacted together as in Procedure A. The product was collected by filtration as a yellow solid (1.86g); m/z 381 (M+1)t. (6-(5-(1,3-Dioxolan-2-yl )-furan-2-vl)-pyridof3.4-dipyrimidin-4-yl)-(4-(3 fluorobenzyloxy)-phen) -amine (6-Chloropyrido[3,4-djpyrimidin-4-yl)-(4-(3-fluorobenzyloxy)-phenyl)-amine (1.85g) and 5-(1,3-dioxolan-2-yl )-2-(tributylsta n nyl)-fu ran (3.82g) in dioxan (40ml) were reacted together as in Procedure B. The mixture was evaporated and the residue suspended in dichloromethane. This was then filtered through Celite" and the' solvent evaporated. The gummy residue was then triturated with hexane giving a beige solid (1.74g); m/z 485 (M+1). 5-(4-(4-(3-Fluorobenz yloxy)-phenylmino)-pyrido[3,4-dipyrimidin-6-yl)-furan-3 carbaldehyde (6-C h loropyrido[3 4-d] pyrimid in-4-yl )-(4-(3-fluorobenzyloxy)-phenyl)-am ine (1g) and 5-(tributylstannyl)-furan-3-carbaldehyde (J.Org.Chem. (1992), 57(11), 3126-31) OAdOcsPatentsMARSPECSPG341 6au.DOC 35 (1 .84g) in dioxan (35ml) were reacted together as in Procedure B. The solvent was evaporated and the residue suspended in dichioromethane. The mixture was filtered through Celite® and then evaporated. The residue was triturated with hexane giving a beige solid (1g); m/z 441 (M+1)* 5-(4-(4-(3-Fluorobenzvloxv)-phenvamino)-pyrido3,4-dlpyrimidin-6-l)-furan-2 carbaldehyde (6-(5-(1,3-Dioxolan-2-yl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-yl)-(4-(3 fluorobenzyloxy)-phenyl)-amine (500mg) was treated with acid as in Procedure C. The product was collected by filtration as a beige solid (251mg); m/z 441 (M+i)*. (4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-(2-(methylthio)-ethvlaminomethyl)-furan-2 vI)-pyrido[3,4-dipvrimidin-4-vl)-amine (5-(4-(4-(3-Fluorobenzyloxy)-phenyl)-pyrido[3,4-d]pyrimidin-6-yI)-furan-2 carbaldehyde (125mg) and (methylthio)ethylamine (0.08ml) in dichloromethane (5ml) were reacted together as in Procedure D. Purification using a Bond Elutim cartridge gave a yellow oil (80mg); m/z 516 (M+1)*. Other suitable intermediates prepared by analogous methods to those described above are: (4-Benzyloxy-3-chlorophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yI)-amine; (4-(3-Fluoro-benzyloxy)-3-chlorophenyl)-6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine; (4-Benzyloxy-3-bromophenyl)-6-ch loro-pyrido[3,4-d] pyrimid in-4-yl)-amine; (4-(3-Fl uoro-benzyloxy)-3-bromophenyl)-6-chloro-pyrido[3,4-d] pyrimid in-4-yl)-a mine; (4-Benzyloxy-3-fluorophenyl)-6-ch loro-pyrido[3,4-dipyrimid in-4-yl)-a mine; (4-(3-Fluoro-benzyloxy)-3-fluorophenyl-6-chloro-pyrido[3,4-d]pyrimidin-4-y)-amine; 5-((4-Benzyloxy-3-chlorophenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2 carbaldehyde; 5-((4-(3-Fluoro-benzyloxy)-3-chlorophenylamino)-pyrido[3,4-dipyrimidin-6-yl)-furan-2 carbaldehyde; 5-((4-Benzyloxy-3-bromophenylamino)-pyrido[3,4-d]pyrimidin-6-y)-furan-2 carbaldehyde; 5-((4-(3-Fluoro-benzyloxy-3-bromophenylamino)-pyrido[3,4-d]pyrimidin-6-yl)-furan-2 carbaldehyde; O:docsPatentsMARSPECSPG341 6au.DOC 36 5-((4-Benzyloxy-3-fluorophenylamino)-pyrido[3,4-djpyrimidin-6-yl)-furan-2 carboxaldehyde; 5-((4-(3-Fluoro-benzyloxy-3-fluorophenylamino)-pyrido[3,4-dpyrimidin-6-yl)furan-2 carbaldehyde; iN-[4-(Benzyloxy)-3-chlorophenyl]-7-fluoro-6-chloro-4-quinazolinamine;
N-[
4
-(
3 -Fluoro-benzyloxy)-3-chlorophenyl]-7-fl uoro-6-ch loro-4-qu inazol ina mine;
N-[
4 -Benzyloxy-3-bromophenyl]-7-fluoro-6-chloro-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-bromophenyl]-7-fluoro-6-chloro-4-quinazolinamine; N-[4-Benzyloxy-3-fluorophenyl]-7-fluoro-6-chloro-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy-3-fluorophenyl]-7-fluoro-6-chloro-4-quinazolinamine; 5-(4-[4-(Benzyloxy)-3-chlorophenylamino]-7-fluoro-quinazolin-6-yl)-furan-2 carbaldehyde; 5-( 4
-[
4
-(
3 -Fluoro-benzyloxy)-3-chlorophenyl]-7-fluoro-quinazolin-6-y)-furan-2 carbaldehyde; 5-( 4
-[
4 -Benzyloxy-3-bromophenyl]-7-fluoro-quinazolin-6-yi)-furan-2-carbaldehyde; 5-( 4
-[
4
-(
3 -Fluoro-benzyloxy)-3-bromoph enyl]-7-fluoro-qu inazolin-6-yl)-fu ran-2 carbaldehyde; 5-[ 4 -Benzyloxy-3-fluorophenyl]-7-fluoro-quinazolin-6-yl)-furan-2-carbaIdehyde 5-( 4 -(3-Fluoro-benzyloxy)-3-fluorophenyll-7-fluoro-quinazolin-6-yl)-furan-2 carbaidehyde. Examples Example I N4 F N (4-(3-Fluorobe nzyloxv)-phenvl )-(6-(5-(f2-methanesuIphonyl-ethylaminolmethvI furan-2-VI)-pyrido 3,4-dlpyrimidin-4-yl)-amine dihydrochloride
(
4
-(
3 -Fluorobenzyloxy)-phenyl)-(6-(5-(2-(methylthio)-ethylaminomethyl)-furan-2-y) pyrido[ 3 ,4-d]pyrimidin-4-yl)-amine (80mg) in methanol (9m) and water (3ml) was treated with Oxone (153mg) at room temperature for 2 days. The mixture was then partitioned between aqueous sodium carbonate solution and dichloromethane. O:docsPatentsMARSPECSPG3 4 16au.DOC 37 The dried organic phase was evaporated and the residue purified by Bond ElutTM cartridge, followed by conversion to the hydrochloride salt, giving a yellow solid (69mg); 5H [ 2 He]DMSO 9.8 (IH,bs) 9.4 (1H,s) 9.3 (1H,s) 8.7 (IH,s) 7.8 (2H,d) 7.3 7.4 (2H,m) 7.0-7.3 (5H,m) 6.8 (1 H,d) 5.3 (2H,s) 4.4 (2H,s) 3.5-3.7 (4H,m) 3.1 (3H,s); m/z 548 (M+1)+. Example 2 ok"N NJC O'F (4-(3-Fluorobenzvloxv)-phenyl)-(6-(4-((2-methanesulphonyl-ethylamino)-methyl) furan-2-yl)-pyrido(3,4-dlpyrimidin-4-vl)-amine dihydrochloride 5-(4-(4-(3-Fluorobenzyloxy)-p henyl )-pyrido[3,4-d] pyrimid in-6-y)-furan-3 carbaldehyde (300mg) and 2-methanesulphonyl-ethylamine (335mg) in dichloromethane (15ml) were reacted together as in Procedure D. Purification using a Bond Elutim cartridge, followed by conversion to the hydrochloride salt, gave a yellow solid (110mg); 8H [ 2
H
6 ]DMSO 9.8 (2H,br) 9.3 (1 H,s) 9.0 (1 H,s) 8.8 (1H,s) 8.2 (IH,s) 8.0 (1H,s) 7.1-7.8 (7H,m) 7.0 (1H,s) 5.2 (2H,s) 4.1-4.3 (4H,brm) 3.3-3.5 (2H,bs) (hidden under H 2 0 peak) 3.2 (3H,s); m/z 548(M+1)*. Example 3 S, N 0N F N) N-{4-[(3-fluorobenzv )oxylphenvll-6-[5-({[2-(methanesulphonvl)ethyllamino}methyl)-2 furyll-4-quinazolinamine Prepared according to Procedure D from 5-(4-{4-(3-fluorobenzyloxy)anilino}-6 quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphony-ethyla mine (1 equiv). 1 H NMR 400 MHz (DMSO-d6) 9.40 (s,IH); 8.67 (s,1H); 8.30 (d,1H); 7.86 (d,1H); 7.75 (d,2H); 7.43 (m,1H); 7.30-7.21 (m,3H); 7.15 (m,1H); 7.07 (d,2H); 6.80 O:docsPatentsMARSPECSPG3416au.DOC 38 (d,1H); 5.15 (s,2H); 4.40 (s,2H); 3.65 (m,2H); 3.40 (m,2H); 3.11 (s,3H); MS mlz 547 (M+1). Example 4 0 N N-f4-[(3-fluorobenzv)oxyl-3-methoxvphenvl}-6-[5-([2 (methanesulphony)ethyllaminolmethyl)-2-furyll-4-quinazolinamine Prepared according to Procedure D from 5-(4-{3-methoxy-4-(3 fluorobenzyloxy)anilino}-6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2 methanesulphonyl-ethylamine (1 equiv). "H NMR 400 MHz (DMSO-d6) 9.22 (s,1H); 8.78 (s,1H); 8.31 (d,IH); 7.88 (d,IH); 7.50-7.08 (m,8H); 6.84 (d,1H); 5.13 (s,2H); 4.42 (s,2H); 3.80 (s,3H); 3.60 (m,2H); 3.40 (m, 2H, obscured by water peak); 3.10 (s,3H); MS m/z 577 (M+1). Example 5 0o F N N N N-{4-[(3-fluorobenzyl)oxyl-3-methoxyphenvl}-6-(2-({[2 (methanesulphonyl)ethyllaminolmethyl)-1,3-thiazol-4-yl}-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-fluorobenzyfoxy)-3 methoxypheny)quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N-bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N (methanesulphonylethyl)-aminomethylthioamide (1 equiv).'H NMR 400 MHz
(CD
3 0D) 9.40 (s, 1H); 8.79 (s, 1H); 8.76 (d, IH); 8.38 (s, 1H); 7.89 (d, 1H); 7.50 (s, 1H); 7.40 (t, 1H); 7.34 (m, IH); 7.27 (d, 1H); 7.22 (d, 1H); 7.08 (d, 1H); 7.03 (t, 1H); 5.19 (s, 2H); 4.81 (s, 2H); 3.85 (m, 2H); 3.75 (m, 2H); 3.10 (s, 3H); MS m/z 594 (M+1)*, 592 (m-1)-. O:docsPatentsMARSPECSPG3416au.DOC 39 Example 6 !S S' F, r NN N-{4-f(3-fluorobenzyl)oxyklhenyl}-6-[2-(f[2-(methanesulphonyl)ethyllamino}methyl) 1,3-thiazol-4-yll-4-quinazolinamine Prepared according to Procedure F from 6-iodo-(4-(3-fluorobenzyloxy)- phenyl) quinazolin-4-ylamine and (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl) aminomethylthioamide (1 equiv). 1 H NMR 400 MHz (CD 3 0D) 9.44 (s, 1H); 8.79 (s, 1H); 8.76 (d, 1H); 8.37 (s, 1H); 7.90 (d, IH); 7.74 (d, 1H); 7.53 (d, 1H); 7.46 (d, 2H); 7.38 (m, 2H); 7.32 (d, 1H); 7.24 (d, 1H); 5.21 (s, 2H); 4.82 (s, 2H); 3.85 (m, 2H); 3.77 (m, 2H); 3.11 (s, 3H); MS m/z 564 (M+1)*, 562 (m-i). Example 7 FO 0. / o N NN N N N-[4-(benzyloxy)-3-fiuorophenvll-6-2-(ff2-(methanesu lphony l)ethyllamino)methyl) 1,3-thiazol-4-yll-4-unazoinanmine Prepared according to Procedure F from 6-iodo-(4-benzyloxy)-3 fluorophenyl)quinazolin-4-ylamine and N-(trifluoroacetyl)-N-(methanesulphonylethyl) aminomethylthioamide (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N bromosuccinimide (1 equiv) and N-(trifl uoroacetyl)-N-(metha nesul phonylethyl) aminomethylthioamide (1 equiv). lH NMR 400 MHz (CD 3 0D) 9.41 (s, IH); 8.77 (d, 1H); 8.75 (s, IH); 8.36 (s, IH); 7.90 (d, 1H); 7.71 (d, 2H); 7.60 (m, 1H); 7.40 (m, 1H); 7.23 (m, IH); 7.11 (d, 2H); 7.03 (m, 1H); 5.17 (s, 2H); 4.81 (s, 2H); 3.85 (m, 2H); 3.76 (m, 2H); 3.10 (s, 3H); MS m/z 564 (M+1), 562 (m-1)-. O:docsPatentsMARSPECSPG3416au.DOC 40 Example 8 20c F N N N-{3-fluoro-4-[(3-fluorobenzvl)oxylphenvll-6-[5-([2 (metha nesulphonyl)ethyllaminolmeth)-2-fu ryll-4-quinazoli namine Prepared according to Procedure D from 5-(4-{3-fluoro-4-(3-fluorobenzyloxy)anilino) 6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl ethylamine (1 equiv). 'H NMR 400 MHz (DMSO-d6) 9.61 (bs, 2H); 9.28 (bs, 1H); 8.80 (s, IH); 8.34 (d, 1H); 7.87 (m, 2H); 7.59 (d, 1H); 7.44 (m, 1H); 7.2 - 7.38 (m, 4H); 7.18 (m, 1H); 6.83 (s, 1H); 5.25 (s, 2H); 4.42 (s, 2H); 3.60 (m, 2H); 3.45 (m, 2H, obscured by water peak); 3.16 (s, 3H); MS m/z 565 (M+1). Example 9 0 F N, N N-{3-fluoro-4-[(3-fluombenzvl)oxylphenvl}-6-[2-({[2 (methanesulphonyl)ethyllaminolmethyl)-1,3-thiazol-4-yil-4-quinazolfinamine Prepared according to Procedure F from 6-iodo-4-(1-benzyl-1H-indazol-5-yl) quinazolin-4-ylamine (1 equiv), 2-ethoxyvinyl-tributylstannane (1 equiv), N bromosuccinimide (1 equiv) and N-(trifluoroacetyl)-N-(methanesulphonylethyl) aminomethylthioamide (1 equiv). H NMR 400 MHz (CD 3 0D) 9.28 (s, 1H); 8.78 (s, IH); 8.74 (d, 1H); 8.31 (s, IH); 7.90 (d, IH); 7.74 (d, 1H); 7.63 (m, IH); 7.54 (m, IH); 7.49 (m, 1H); 7.37 (m, 1H); 7.25 (m, 2H); 7.05 (m, 1H); 5.24 (s, 2H); 4.77 (s, 2H); 3.81 (m, 2H); 3.72 (m, 2H); 3.10 (s, 3H); MS m1z 582 (M+1)*, 580 (m-1) O:docsPatentsMARSPECSPG3416au.DOC 41 Example 10 NQF N N-(3-Fluoro-4-benzvloxyphenyl-6-[5-(f[2-(methanesulphonvl)ethyllaminolmethyl)-4 furyl]-4-quinazolinamine Prepared according to Procedure D from 5-(4-{3-fluoro-4-benzyloxyanilino}-6 quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv). 'H NMR 400 MHz (DMSO-d6) 8.83 (s,1H); 8.35 (d,1H); 7.89 (d,1H); 7.83 (d,1H); 7.59 (d,1H); 7.48-7.31 (m,7H); 7.26 (s,1H); 6.83 (d,1H); 5.21 (s,2H); 4.42 (s,2H); 3.60 (m,2H); 3.44 (m, 2H, obscured by water peak); 3.12 (s,3H); MS m/z 547 (M+H*). Example 11 S~ N
-
-'
N-(3-Chloro-4-benzvloxvphenyl)-6-[5-({[2-(methanesulphonvl)ethyllaminolmethyl)-4 furyll-4-qiuinazolinamine Prepared according to Procedure D from 5-(4-{3-chloro-4-benzyloxyanilino}-6 quinazolinyl)-furan-2-carbaidehyde (0.6 equiv) and 2-methanesulphonyl-ethylamine (1 equiv). 'H NMR 400 MHz (DMSO-d6) 9.71 (bs, 2H); 9.45 (bs, 1H); 8.86 (s, 1H); 8.36 (d, 1H); 7.98 (d, 1H); 7.90 (d, 1H); 7.74 (d, IH); 7.49-7.44 (m, 2H); 7.40 (m, 2H); 7.35-7.30 (m, 2H); 7.28 (d, tH); 6.83 (d, 1 H); 5.25 (s, 2H); 4.42 (s, 2H); 3.62 (m, 2H); 3.44 (m, 2H); 3.12 (s, 3H); MS m/z 563 (M+H*). O:docsPatentsMARSPECSPG3416au.DOC 42 Example 12 o a N g)CI N-f3-Chloro-4-f(3-fl uorobenzvl)axylphenyl}-6-[5-({f2 (methanesulphonvl)ethyllaminomethyl)-2-furyll-4-quinazolinamine Prepared according to Procedure D from 5-(4-{3-chloro-4-(3-fluorobenzyloxy) anilino}-6-quinazolinyl)-furan-2-carbaldehyde (0.6 equiv) and 2-methanesulphonyl ethylamine (1 equiv). 'H NMR 400 MHz (DMSO-d6) 9.60 (bs, 1H); 9.32 (bs, 1H); 8.82 (bs, 1H); 8.34 (d, 1H); 8.0 (s, 1H); 7.88 (d, 1H); 7.74 (d, 1H); 7.45 (m, 1H); 7.34 7.23 (m, 4H); 7.17 (m, 1H); 6.83 (d, 1H); 5.27 (s, 2H); 4.42 (s, 2H); 3.59 (m, 2H); 3.40 (m, 2H, obscured by waterpeak); 3.12 (s, 3H); MS m/z 581 (M+H*). Further Examples The compounds in Lists 1 to 9 above and their hydrochloride salts, if appropriate, are prepared by analogous techniques using the appropriate starting materials. Biological Data Compounds of the present invention were tested for protein tyrosine kinase inhibitory activity in substrate phosphorylation assays and cell proliferation assays. Substrate Phosphorylation Assay The substrate phosphorylation assays use baculovirus expressed, recombinant constructs of the intracellular domains of c-erbB-2 and c-erbB-4 that are constitutively active and EGFr isolated from solubilised A431 cell membranes. The method measures the ability of the isolated enzymes to catalyse the transfer of the g-phosphate from ATP onto tyrosine residues in a biotinylated synthetic peptide (Biotin-GluGluGuGluTyrPheGluLeuVal). Substrate phosphorylation was detected following either of the following two procedures: a.) c-ErbB-2, c-ErbB4 or EGFr were incubated for 30 minutes, at room temperature, with 10mM MnCI2, 10mM ATP, 5 mM peptide, and test compound (diluted from a 5mM stock in DMSO, final DMSO concentration is 2%) in 40mM HEPES buffer, pH 7.4. The reaction was stopped by the addition of EDTA (final concentration 0.15mM) and a sample was transferred to O:docsPatentsMARSPECSPG3416au.DOC 43 a streptavidin-coated 96-well plate. The plate was washed and the level of phosphotyrosine on the peptide was determined using a Europium-labelled antiphosphotyrosine antibody and quantified with a time-resolved fluorescence technique. b.) ErbB2 was incubated for 50 minutes at room temperature with 15 mM MnCI2, 2 mM ATP, 0.25 mCi [y- 33 P] ATP/well, 5 mM peptide substrate, and test compound (diluted from a 10mM stock in DMSO, final DMSO concentration is 2%) in 50 mM MOPS pH 7.2. The reaction was terminated by the addition of 200 ml of PBS containing 2.5 mg/ml streptavidin-coated SPA beads (Amersham inc.), 50 mM ATP, 10 mM EDTA and 0.1%TX-100. The microtitre plates were sealed and SPA beads were allowed to settle for at least six hours. The SPA signal was measured using a Packard Topcount 96-well plate scintillation counter (Packard Instrument Co., Meriden, CT). The results are shown in Tables 1A (examples 1 and 2) and 1B (examples 3 to 12) as the IC 50 values. Table 1A Substrate Phos ho lation Example erbB2 - assay (b) EGF-r - assay (a) 1 +++
+
2 ++ Table 1B Substrate Phosphorlation Exam le_ erbB2 - assay (b) 3 +++ 4 +++ 5 ++ 6 +++ 7 +++ 8 + 9 +++ 10 +++ 11 ++ 12 ++ O:docsPatentsMARSPECSPG341 6au.DOC 44 ICso values Symbol 0.10 - 1.0 M ++ 1.0 - 10.0 pM + > 10.0 8M Not determined ND Cellular assays: Methylene Blue Growth Inhibition Assay Human breast (BT474), head and neck (HN5) and gastric tumor (N87) cell lines were cultured in low glucose DMEM (Life Technologies 12320-032) containing 10% fetal bovine serum (FBS) at 370C in a humidified 10% C02, 90% air incubator. The SV40 transformed human mammary epithelial cell line HB4a was transfected with either human H-ras cDNA (HB4a r4.2) or the human c-erbB2 cDNA (HB4a c5.2). The HB4a clones were cultured in RPMI containing 10% FBS, insulin (5 pag/ml), hydrocortisone (5 ptg/mI), supplemented with the selection agent hygromycin B (50ptg/ml). Cells were harvested using trypsin/EDTA, counted using a haemocytometer, and plated in 100 ml of the appropriate media, at the following densities, in a 96-well tissue culture plate (Falcon 3075): BT474 10,000 cells/well, HN5 3,000 cells/well, N87 10,000 cells/well, HB4a c5.2 3,000 cells/well, HB4a r4.2 3,000 cells/well. The next day, compounds were diluted in DMEM containing 100 mg/mi gentamicin, at twice the final required concentration, from 10mM stock solutions in DMSO. 100ml/well of these dilutions were added to the 100ml of media currently on the cell plates. Medium containing 0.6% DMSO was added to control wells. Compounds diluted in DMEM were added to all cell lines, including the HB4a r4.2 and HB4a c5.2 cell lines. The final concentration of DMSO in all wells was 0.3%. Cells were incubated at 370C, 10% C02 for 3 days. Medium was removed by aspiration. Cell biomass was estimated by staining cells with 100pI per well methylene blue (Sigma M9140, 0.5% in 50:50 ethanol:water), and incubation at room temperature for at least 30 minutes. Stain was removed, and the plates rinsed under a gentle stream of water, and air-dried. To release stain from the cells I 00pl of solubilization solution was added (1% N-lauroyl sarcosine, Sodium salt, Sigma L5125, in PBS), and plates were shaken gently for about 30 minutes. Optical density at 620 nM was measured on a microplate reader. Percent inhibition of cell growth was calculated relative to vehicle treated control wells. Concentration of compound that inhibits 50% of cell growth (ICso) was interpolated using nonlinear O:docsPatentsMARSPECSPG3416au.DOC 45 regression (Levenberg-Marquardt) and the equation, y = Vmax*(1-(x/(K+x))) + Y2, where "K" was equal to the IC 5 0 . Table 2 illustrates the inhibitory activity of compounds of the present invention as 5 IC 50 values in pM against a range of tumor cell lines. Table 2 Example Cell Proliferation HB4a HB4a BT474 HN5 N87 erbB2 ras 1 +++ + +++ ++ + 2 +++ + +++ +++ +++ 3 +++ ++ +++ +.+ +++ 4 +++ ++ +++ +++ +++ 5 +++ - +++ ++ +++ 6 +++ - +++ +++ +++ 7 +++ - +++ +++. 8 +++ ++ +++ +++ +++ 9 +++ - +++ +++ +++ 10 +++ ++ +++ +++ +++ 11 +++ + +++ . ++ +++ 12 ++ - +++ +++ +++ 1C 5 0 value Symbol <5 M +++ 5 - 25 pM ++ 25-50 pM + >50 pM Not determined ND O:docsPatentsMARSPECSPG3416au.
DOC
-46 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or 5 group of integers or steps. The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form or suggestion that that prior art forms part of the common general knowledge in Australia. 10 15 Pages 47 to 115 are intentionally blank

权利要求:
Claims (32)
[1] 1. A compound of formula (1) HN H YN N I or a salt or solvate thereof; wherein Y is CR' and V is N; or Y is CR' and V is CR
[2] 2 R' represents a group CH3SO 2 CH 2 CH 2 NHCH 2 -Ar-, wherein Ar is selected from furan and thiazole, each of which may optionally be substituted by one or two halo, C.4 alkyl or C14 alkoxy groups; R 2 is hydrogen or C14 alkoxy; or R 2 is halo; R 3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl, benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl; R 4 is halo or C14 alkoxy or is not present; wherein either (a) R 3 represents
[3] 3-fluorobenzyloxy; and/or (b) R 4 is selected from halo and -is substituted in the 3-position of the phenyl ring; and halo represents fluoro, chloro or bromo. -117 2. A compound as claimed in claim 1 wherein R 2 is hydrogen or methoxy; or R 2 is fluoro. 3. A compound as claimed in claim 1 or claim 2 wherein the group Ar represents unsubstituted furan or thiazole.
[4] 4. A compound as claimed in any one of claims 1 to 3 wherein R 3 represents benzyl, pyridylmethyl, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl.
[5] 5. A compound as claimed in any one of claims 1 to 4 wherein the R 4 group is not present.
[6] 6. A compound as claimed in any one of claims 1 to 5 wherein the phenyl group together with the substituent(s) R 3 and R 4 represents (3 fluorobenzyloxy)phenyl.
[7] 7. A compound as claimed in any one of claims I to 4 wherein the phenyl group together with the substituent(s) R 3 and R 4 represents 3 fluorobenzyloxy-3-chlorophenyl, benzyloxy-3-chlorophenyl, benzyloxy-3 fluorophenyl, or 3-fluorobenzyloxy-3-fluorophenyl.
[8] 8. A compound as claimed in claim 1 selected from: (4-(3-Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl ethylamino)methyl)-furan-2-yl)-pyrid o[3,4-dlpyrmidin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphony-ethylamino) methyl)-furan-2-yl)-pyrido[3,4-d]pyrimidin-4-y)-amine; N-{4-[(3-Fluorobenzyl)oxy]pheny-6-[5-({[2 (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{4-[(3-Fluorobenzyl)oxy]-3-methoxyphenyl}-6-[5-({[2 (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-(4-[(3-Fluorobenzyl)oxy]-3-methoxyphenyl}-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; - 118- N-{4-[(3-Fluorobenzy)oxy]phenyl}-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl-4-quinazolinamine; N-{3-Fluoro-4-[(3-fluorobenzyl)oxyphenyl)-6-[5-({[2 (methanesulphonyl)ethyllamino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Fluoro-4-[(3-fluorobenzyl)oxy]pheny}-[2-({[2 (methanesulphonyl)ethyl]aminolmethyl)-1 ,3-thiazol-4-yl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]pheny}-6-[5-({[2 (methanesulphonyl)ethyl amino}methyl)-2-furyl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
[9] 9. A compound as claimed in claim 1 selected from: N-[4-(Benzyloxy)-3-fluorophenyl]-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-ylJ-4-quinazolinamine; N-(3-Fluoro-4-benzyloxyphenyl)-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-4-furyl]-4-quinazolinamine; N-(3-Chloro-4-benzyloxyphenyl)-6-[2-({[2 (methanesulphonyl)ethyljamino}methyl)-4-fury]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
[10] 10. A compound as claimed in claim 1 selected from: (4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; ( 4 -( 3 -Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-thiazol-5-yl)-pyrido[3,4-d]pyrimidin-4-yl)-amine; ( 4 -(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesuphonyl ethylamino)methyl)-thiazol-2-y)-pyrido[3,4-d]pyrimidin-4-yl)-amine; ( 4 -( 3 -Fluorobenzyloxy)-phenyl)-(6-(5-((2-methanesulphonyl ethylamino)methyl)-thiazol-2-yl)-pyrdo[3,4-d]pyrimidin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(4-((2-methanesulphonyl ethylamino)methyl)-furan-2-y)-quinazolin-4-yl)-amine; (4-(3-Fluorobenzyloxy)-phenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine; ( 4 -(S-Fluorobenzyloxy)-phenyl)-(6-(2-((2methanesulphonyl ethylam ino)methyl)-thiazol-s-ylyq uinazoiin-4-yI)-amine; ( 4 -( 3 -Fluorobenzloxy)-phenyly(6(4-((2-metha nesuiphonyl ethylamino)methy)Athiazok-2yI) 1 uinazolin-4-yI)-amine; ( 4 -( 3 -Fluorobenzyloxy)phenyI)-(6.{5.q2-methanesulphonyj ethylamino)methyl)-th iazoi-2-yI)-q uinazolin-4-yI)-amine; ( 4 -( 3 -Fluoro-benzyloxy)-3chloropheny)(6.(5((2-methanesulph 0 ny ethylamino)methy)furan2yI)-pyido[3,4.jpyrjmdn4yi) 0 amine'; ( 4 -( 3 -Fiuoro-benzyloxy)-3-.bromopheny)(6(&((2-metaneuphoyl etyaiomty)frn2y)prio34dpfmdn4y)aie (4(-loobnyoy--loohnl-6(-(-ehnslhnl ethylamino)methy)furan2yi)fpyddo[3,4..lpyrimidjn-4-yl)-ajf 6 ; ( 4 -( 3 -Fluoro-benzy~oxy)-3-choropheny-(6j2-((2-methn 5 ulphonyl ethylamino)methy)-thiazo.4-yI)-pydidof3 4-d]pyrimidin-4-yI)-amine; ( 4 -( 3 -Fluaro-benzyioxy)-3bromopheny)(e(2-((2-methan 5 ulph 0 ny[ ethYiamino)methyI)-thiazoI-4yry-pyaido[3,4..pyrimjiin-4-yi)-amine; (4(-loobnyoy--loohnl-6(-(-ehnslhnl etyaiomty)tizl4y)p~d[,-lyiii--l-mn, (4-(3-Fluoro-benzyloxy)-3-.ch Ioraphenyi)-(6-(2-((2-methanesulphonyl. ethylamino)methy)4thiazoi4yI).quinz 0 in4y;) 8 amjfl; (4-(3-FI r-ez~x)3brmpey)(-2((-ehnslhnt ethylamino)metlyl)-thiazo..4yI).q uinazolin-4-yI)-amine; ( 4 -( 3 -Fluoro-benzyloxy)-3tbromopheny)(6(5-(2methanesuph 0 nyl ethylamino)-methy)-furan2yI)-quinazolinA4-yt)-amine; N-E4-(3-Fluoro-benzyloxy)-a..ch Ioropheny]-7-methoxy-6-5([2. (mtaeupoy~tyaiomty)2frl4qiaoiaie N-[ 4 -( 3 -FIuioro-benzyaxyy.3bwmopheny]7-methoxy-4[5.qf[.. (methanesulphony)ethyaamino}memhyI)-2fuylIA..q uinazolinamine; N-4(-loobnyoy--lorpey]7mtoy6[-{2 (metha nesu Iphonyl)ethyl]amino) iethyl)-2-furyl]-4.q uinazolinamine; N-[4-(3-Fiuoro-benzyloxy)-3.sjhorophenyll-7-fluoro-6-[5-({f2 (methanesulpoy ty~mnlehl-2frl--unzlnmn N-[ 4 -(-Fiuoro-benzyoxy)3bmmopheny]qfiuor 0 -6f5({[2 (methanesulphony)ethyllam ino~methyl)-24furyI]A4-quinazolinamjne N-[ 4 -( 3 -Fluoro-benzyloxy)..3.fluorophenyj7-fl uoro-6-(5-({f2 (mtaeslhniehlaiomty)2frl--unzlnmn N-[4-(3-Fluoro-benzroxyy-3ch Iorophenyi-7-methoxy6[2(([2. (methanes ulp honylethyqam ino}mothyl)-1 ,34iz 4yi--unzoiai -120 N-[4-(3-Fluoro-benzyloxy)-3-bromophenyl]-7-methoxy-6-[2-({[2 (methanesulphony)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-fluorophenyl]-7-methoxy-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-chlorophenyl]-7-fluoro-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-bromophenyl-7-fuoro-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(3-Fluoro-benzyloxy)-3-fluorophenyl]-7-fluoro-6-[2-({[2 (methanesulphony)ethylaminomethyl)-1,3-thiazol-4-yl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof.
[11] 11. A compound as claimed in claim 1 selected from: (4-Benzyloxy-3-chlorophenyl)-(6-(5-((2-methanesulphonyl ethylamino)methyl)-furan-2-yl)-pyrido[3,4-djpyrimidin-4-yl)-amine; ( 4 -Benzyloxy-3-bromophenyl)-(6-(5-((2-methanesulphonyl ethylamino)methyl)-furan-2-yl)-pyrido[3,4-dpyrimidin-4-yl)-amine; (4-Benzyloxy-3-fluorophenyl)-(6-(5-((2-methanesulphonyl-ethylamino)methyl) furan-2-yl)-pyrido[3,4-dlpyrimidin-4-yI)-amine; (4-Benzyloxy-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl) thiazol-4-yl)-pyrido[3,4-dJpyrimidin-4-yl)-amine; (4-Benzyloxy-3-bromophenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-thiazol-4-yl)-pyrido[3,4-djpyrimidin-4-yl)-amine; ( 4 -Benzyloxy-3-fluorophenyl)-(6-(2-((2-methanesulphony-ethylamino)methyl) thiazol-4-yl)-pyrido[3,4-dlpyrimidin-4-yl)-amine; (4-Benzyloxy-3-chlorophenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine (4-Benzyloxy-3-bromophenyl)-(6-(2-((2-methanesulphonyl ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine; ( 4 -Benzyloxy-3-bromophenyl)-(6-(5-((2methanesulphony-ethylamino) methyl)-furan-2-yI)-quinazolin-4-yl)-amine; N-[4-(Benzyloxy)-3-chlorophenyl]-7-methoxy-6-[5-({[2 (methanesulphonyl)ethylamino}methyl)-2-furyl]-4-quinazolinamine; N-[4-Benzyloxy-3-bromophenyl]-7-methoxy-6-[5-({[2 (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-[4-Benzyloxy-3-fluorophenyl]-7-methoxy-6-[5-({[2 (methanesulphonyl)ethylamino}methyl)-2-furyl]-4-quinazolinamine; - 121 N-[4-(Benzyloxy)-3-chlorophenyl]-7-fluoro-6-[5-({[2 (methanesulphonyl)ethyl]amino)methyl)-2-furyl]-4-quinazolinamine; N-[4-Benzyloxy-3-bromophenyl]-7-fluoro-6-[5-({[2 (methanesulphonyl)ethyl]aminomethyl)-2-furyl]-4-quinazolinamine N-[4-Benzyloxy-3-fluorophenyl]-7-fluoro-6-[5-({[2 (methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine N44-(Benzyloxy)-3-chloropheny]-7-methoxy-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-Benzyloxy-3-bromophenyl]-7-methoxy-6-[2-({[2 (methanesulphony)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-Benzyloxy-3-fluorophenyl]-7-methoxy-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-(Benzyloxy)-3-chlorophenyl]-7-fluoro-6-[2-({[2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-Benzyloxy-3-bromophenyl]-7-fluoro-6-[2-({[2 (methanesulphonyl)ethyl]amino)methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; N-[4-Benzyloxy-3-fluorophenyl]-7-fluoro-6-[2-({[2 (methanesulphonyl)ethylamino}methyl)-1,3-thiazol-4-yl]-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts or solvates thereof.
[12] 12. A compound as claimed in claim 8 selected from: N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-(([2 (methanesulphonyl)ethyl]amino}methyl)-2-furylJ-4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
[13] 13. A compound as claimed in claim 10 selected from: N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[2-([2 (methanesulphonyl)ethyl]amino}methyl)-1,3-thiazol4-yl]4-quinazolinamine; and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof.
[14] 14. A compound as claimed in claim 10 selected from: N-{3-Bromo-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2 (methanesulphonyl)ethyljamino}methyl)-2-furyl]-4-quinazolinamine; -122 and salts or solvates thereof, particularly pharmaceutically acceptable salts thereof
[15] 15. A compound as claimed in any one of claims 1 to 14 which inhibits both c-erbB-2 and EGF-R receptor kinases.
[16] 16. A process for the preparation of a compound of formula (1) as defined in claim 1 which comprises the steps: (a) the reaction of a compound of formula (11) Y N N H wherein Y' is CL' and V' is N; or Y' is CL' and V' is CR 2 ; wherein R 2 is as defined in claim 1, and L and L' are suitable leaving groups, with a compound of formula (111) R 3 NH 2 wherein R 3 and R 4 are as defined in claim 1, to prepare a compound of formula (IV) H N H -123 and subsequently (b) reaction with appropriate reagent(s) to substitute the group R 1 by replacement of the leaving group L'; and, if desired, (c) subsequently converting the compound of formula (1) thereby obtained into another compound of formula (1) by means of appropriate reagents.
[17] 17. A process for the preparation of a compound of formula (1) as defined in claim 1 which comprises the steps: (a) reacting a compound of formula (IV) as defined in claim 16 with appropriate reagent(s) to prepare a compound of formula (Vill) HN4 HN H y" N H (VII) wherein R 3 and R 4 are as defined in claim 1; Y" is CT and V" is N; or Y" is CT and V" is CR 2 wherein R 2 is as defined in claim I and T is an appropriately functionalised group; and (b) subsequently converting the group T into the group R 1 by means of appropriate reagent(s); and, if desired, (c) subsequently converting the compound of formula (1) thereby obtained into another compound of formula (1) by means of appropriate reagents.
[18] 18. A pharmaceutical formulation comprising at least one compound of formula (1) as claimed in any one of claims 1 to 15 or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers, diluents or excipients. - 124
[19] 19. A pharmaceutical formulation as claimed in claim 18 in unit dosage form and containing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in an amount of from 70 to 700mg.
[20] 20. A compound of formula (1) as claimed in any one of claims 1 to 15 or a pharmaceutically acceptable salt or solvate thereof for use in therapy.
[21] 21. The use of a compound of formula (1) as claimed in any one of claims 1 to 14 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for the treatment of a disorder mediated by c erbB-2 and/or EGF-R protein tyrosine kinase activity.
[22] 22. The use as claimed in claim 21 wherein the compound is as claimed in claim 15.
[23] 23. The use as claimed in claim 22 wherein the compound is as claimed in any one of claims 12 to 14.
[24] 24. The use as claimed in any one of claims 21 to 23 in the preparation of a medicament for the treatment of cancer and malignant tumours.
[25] 25. The use as claimed in any one of claims 21 to 23 in the preparation of a medicament for the treatment of psoriasis.
[26] 26. A method of treatment of a human or animal subject suffering from a disorder mediated by c-erbB-2 and/or EGF-R protein tyrosine kinase activity which comprises administering to said subject an effective amount of a compound of formula (I) as claimed in any one of claims 1 to 14.
[27] 27. A method as claimed in claim 26 wherein the compound is as claned in claim 15.
[28] 28. A method as claimed in claim 27 wherein the compound is as claimed in any one of claims 12 to 14. PME~sc311% 11-ixnrspaend~oc-13 0n12 - 125
[29] 29. A method as claimed in any one of claims 26 to 28 for the treatment of cancer and malignant tumours.
[30] 30. A method as claimed in any one of claims 26 to 28 for the treatment of 5 psoriasis.
[31] 31. A compound as claimed in claim 1 substantially as hereinbefore described with reference to the examples. 10
[32] 32. A process as claimed in claims 16 or 17 substantially as hereinbefore described with reference to the examples. DATED this 21't day of March 2002 15 Glaxo Group Limited by Davies Collison Cave Patent Attorneys for the Applicant

类似技术:

---

公开号 | 公开日 | 专利标题

---

CA2317589C|2007-08-07|Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

---

US7157466B2|2007-01-02|Quinazoline ditosylate salt compounds

---

GB2345486A|2000-07-12|Heteroaromatic protein tyrosine kinase inhibitors

---

WO2001004111A1|2001-01-18|Anilinoquinazolines as protein tyrosine kinase inhibitors

---

MXPA00006824A|2001-07-31|Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

同族专利:

---

公开号 | 公开日

---

ES2262087T3|2006-11-16|

---

PT1454907E|2009-02-18|

---

HU0100941A2|2001-09-28|

---

AU749549B2|2002-06-27|

---

GEP20022678B|2001-12-10|

---

CA2317589A1|1999-07-15|

---

NO20003561D0|2000-07-11|

---

BR9906904B1|2011-05-03|

---

DE69918528T2|2005-07-28|

---

US20070015775A1|2007-01-18|

---

PL192746B1|2006-12-29|

---

JP2002326990A|2002-11-15|

---

SI1454907T1|2009-04-30|

---

EP1047694B1|2004-07-07|

---

IS5549A|2000-06-27|

---

LU91475I2|2008-11-10|

---

CZ20002587A3|2001-05-16|

---

WO1999035146A1|1999-07-15|

---

ES2319119T3|2009-05-04|

---

US20070238875A1|2007-10-11|

---

SI1047694T1|2005-02-28|

---

IL137041A|2006-10-05|

---

CO4820390A1|1999-07-28|

---

LU91475I9|2019-01-02|

---

CN1134438C|2004-01-14|

---

EP1454907A1|2004-09-08|

---

US20100120804A1|2010-05-13|

---

EP1460072A1|2004-09-22|

---

EE04616B1|2006-04-17|

---

DK1047694T3|2004-11-08|

---

US20020147205A1|2002-10-10|

---

DK1460072T3|2006-07-31|

---

DE69918528D1|2004-08-12|

---

GB9800569D0|1998-03-11|

---

HRP20000469A2|2001-06-30|

---

HK1031883A1|2001-06-29|

---

JP3390741B2|2003-03-31|

---

RS49779B|2008-06-05|

---

KR20010015902A|2001-02-26|

---

CA2317589C|2007-08-07|

---

NO2008017I1|2008-12-01|

---

HRP20060387A2|2008-02-29|

---

AT322491T|2006-04-15|

---

ES2221354T3|2004-12-16|

---

US7109333B2|2006-09-19|

---

IL137041D0|2001-06-14|

---

SI1460072T1|2006-08-31|

---

BR9906904A|2000-10-17|

---

AP2000001861A0|2000-09-30|

---

EA200000637A1|2001-02-26|

---

MA26596A1|2004-12-20|

---

HU227593B1|2011-09-28|

---

ME00757B|2008-06-05|

---

NO20003561L|2000-09-11|

---

NO316176B1|2003-12-22|

---

AT270670T|2004-07-15|

---

NL300360I2|2009-02-02|

---

PL341595A1|2001-04-23|

---

TR200002015T2|2001-01-22|

---

PE20000230A1|2000-04-03|

---

CZ298047B6|2007-06-06|

---

EP1047694A1|2000-11-02|

---

KR100569776B1|2006-04-11|

---

UA66827C2|2004-06-15|

---

AP1446A|2005-07-19|

---

DE122008000048I1|2009-01-02|

---

US20130310562A1|2013-11-21|

---

AR015507A1|2001-05-02|

---

YU44800A|2002-11-15|

---

US8912205B2|2014-12-16|

---

NL300360I1|2008-11-03|

---

SK10502000A3|2001-08-06|

---

NO2008017I2|2011-10-17|

---

AR066982A2|2009-09-23|

---

US8513262B2|2013-08-20|

---

US20150065527A1|2015-03-05|

---

PT1047694E|2004-11-30|

---

TW477788B|2002-03-01|

---

MY124055A|2006-06-30|

---

DK1454907T3|2009-03-09|

---

EP1460072B1|2006-04-05|

---

US20050130996A1|2005-06-16|

---

US20030176451A1|2003-09-18|

---

CN1292788A|2001-04-25|

---

DE69930773T2|2006-09-28|

---

EE200000411A|2001-12-17|

---

PT1460072E|2006-07-31|

---

HRP20000469B1|2007-05-31|

---

US20160339027A1|2016-11-24|

---

NZ505456A|2003-06-30|

---

US20160051551A1|2016-02-25|

---

BG104668A|2001-04-30|

---

EP1454907B1|2008-12-17|

---

BG64825B1|2006-05-31|

---

SK285405B6|2007-01-04|

---

AU2278399A|1999-07-26|

---

CY1108859T1|2014-07-02|

---

IS2276B|2007-09-15|

---

US6713485B2|2004-03-30|

---

DE69940128D1|2009-01-29|

---

AU749549C|2003-03-20|

---

DE69930773D1|2006-05-18|

---

EA002455B1|2002-04-25|

---

US9199973B2|2015-12-01|

---

HU0100941A3|2002-09-30|

---

JP2002500225A|2002-01-08|

---

AT417847T|2009-01-15|

---

US6727256B1|2004-04-27|

---

EG24743A|2010-07-14|

---

OA11444A|2004-04-29|

---

ZA99172B|2000-07-11|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US4074057A|1973-12-12|1978-02-14|Takeda Chemical Co., Ltd.|2-Halopropionic acid and its derivatives|

---

US4166735A|1977-01-21|1979-09-04|Shell Oil Company|Cycloalkanecarboxanilide derivative herbicides|

---

EP0222839A4|1985-05-17|1988-11-09|Univ Australian|Antimalarial compounds.|

---

US5141941A|1988-11-21|1992-08-25|Ube Industries, Ltd.|Aralkylamine derivatives, and fungicides containing the same|

---

US5034393A|1989-07-27|1991-07-23|Dowelanco|Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives|

---

BR9101256A|1990-03-30|1991-11-05|Dowelanco|COMPOUND, FUNGICIDE COMPOSITION, FUNGICIDE PROCESS, INSECTICIDE OR ACARICIDE COMPOSITION AND INSECTICIDE OR ACARICIDE PROCESS|

---

US5710158A|1991-05-10|1998-01-20|Rhone-Poulenc Rorer Pharmaceuticals Inc.|Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase|

---

US5480883A|1991-05-10|1996-01-02|Rhone-Poulenc Rorer Pharmaceuticals Inc.|Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase|

---

DE4131924A1|1991-09-25|1993-07-08|Hoechst Ag|SUBSTITUTED 4-ALKOXYPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL|

---

GB9127252D0|1991-12-23|1992-02-19|Boots Co Plc|Therapeutic agents|

---

GB9300059D0|1992-01-20|1993-03-03|Zeneca Ltd|Quinazoline derivatives|

---

WO1993018035A1|1992-03-04|1993-09-16|Abbott Laboratories|Angiotensin ii receptor antagonists|

---

WO1993017682A1|1992-03-04|1993-09-16|Abbott Laboratories|Angiotensin ii receptor antagonists|

---

US5326766A|1992-08-19|1994-07-05|Dreikorn Barry A|4-phenyl)ethoxy)quinazoline and analogues thereof|

---

DE4308014A1|1993-03-13|1994-09-15|Hoechst Schering Agrevo Gmbh|Condensed nitrogen heterocycles, processes for their preparation and their use as pesticides and fungicides|

---

GB9312891D0|1993-06-22|1993-08-04|Boots Co Plc|Therapeutic agents|

---

IL112249A|1994-01-25|2001-11-25|Warner Lambert Co|Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds|

---

US5654307A|1994-01-25|1997-08-05|Warner-Lambert Company|Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family|

---

AU2096895A|1994-03-07|1995-09-25|Sugen, Incorporated|Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof|

---

GB9510757D0|1994-09-19|1995-07-19|Wellcome Found|Therapeuticaly active compounds|

---

TW321649B|1994-11-12|1997-12-01|Zeneca Ltd||

---

GB9424233D0|1994-11-30|1995-01-18|Zeneca Ltd|Quinazoline derivatives|

---

ES2203642T3|1995-06-07|2004-04-16|Pfizer Inc.|HETEROCICLIC PYRIMIDINE DERIVATIVES WITH CONDENSED RINGS.|

---

GB9514265D0|1995-07-13|1995-09-13|Wellcome Found|Hetrocyclic compounds|

---

AR004010A1|1995-10-11|1998-09-30|Glaxo Group Ltd|HETERO CYCLIC COMPOUNDS|

---

WO1997018212A1|1995-11-14|1997-05-22|Pharmacia & Upjohn S.P.A.|Aryl and heteroaryl purine compounds|

---

GB9603095D0|1996-02-14|1996-04-10|Zeneca Ltd|Quinazoline derivatives|

---

HRP970371A2|1996-07-13|1998-08-31|Kathryn Jane Smith|Heterocyclic compounds|

---

ID19609A|1996-07-13|1998-07-23|Glaxo Group Ltd|HETEROSICLIC COMPOUNDS|

---

PE91098A1|1996-07-13|1999-01-15|Glaxo Group Ltd|DERIVATIVES OF PIRIDO [3,4-d] PIRIMIDINA|

---

ID18494A|1996-10-02|1998-04-16|Novartis Ag|PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT|

---

GB9800569D0|1998-01-12|1998-03-11|Glaxo Group Ltd|Heterocyclic compounds|

---

OA12291A|2000-06-22|2004-03-18|Pfizer Prod Inc|Substituted bicyclic derivatives for the treatmentof abnormal cell growth.|

---

JP4102185B2|2000-06-30|2008-06-18|グラクソグループリミテッド|Quinazoline ditosylate compound|

---

WO2002056912A2|2001-01-16|2002-07-25|Glaxo Group Limited|Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent|

---

NZ534171A|2002-02-01|2007-06-29|Astrazeneca Ab|Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability|

---

US7488823B2|2003-11-10|2009-02-10|Array Biopharma, Inc.|Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors|EP1005470B1|1997-08-22|2007-08-01|AstraZeneca AB|Oxindolylquinazoline derivatives as angiogenesis inhibitors|

---

GB9800569D0|1998-01-12|1998-03-11|Glaxo Group Ltd|Heterocyclic compounds|

---

ES2241324T3|1998-10-08|2005-10-16|Astrazeneca Ab|DERIVATIVES OF QUINAZOLINA.|

---

GB2345486A|1999-01-11|2000-07-12|Glaxo Group Ltd|Heteroaromatic protein tyrosine kinase inhibitors|

---

CN100360505C|1999-02-10|2008-01-09|阿斯特拉曾尼卡有限公司|Quinazoline derivatives as angiogenesis inhibitors|

---

GB9910579D0|1999-05-08|1999-07-07|Zeneca Ltd|Chemical compounds|

---

GB9910580D0|1999-05-08|1999-07-07|Zeneca Ltd|Chemical compounds|

---

CA2375259C|1999-06-21|2009-04-28|Boehringer Ingelheim Pharma Kg|Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them|

---

JP2003504363A|1999-07-09|2003-02-04|グラクソグループリミテッド|Anilinoquinazolines as protein tyrosine kinase inhibitors|

---

US6933299B1|1999-07-09|2005-08-23|Smithkline Beecham Corporation|Anilinoquinazolines as protein tyrosine kinase inhibitors|

---

HU0300059A3|1999-09-21|2003-08-28|Astrazeneca Ab|Quinazoline derivatives, process for their preparation, pharmaceutical compositions containing the compounds and use of the new and known quinazoline derivatives against proliferative disease|

---

CA2632556C|1999-11-11|2012-01-03|Osi Pharmaceuticals, Inc.|Stable polymorph of n--6,7-bis-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof|

---

JP2003520855A|2000-01-28|2003-07-08|アストラゼネカアクチボラグ|Chemical compound|

---

GB0002952D0|2000-02-09|2000-03-29|Pharma Mar Sa|Process for producing kahalalide F compounds|

---

US6521618B2|2000-03-28|2003-02-18|Wyeth|3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors|

---

AR035851A1|2000-03-28|2004-07-21|Wyeth Corp|3-CIANOQUINOLINS, 3-CIANO-1,6-NAFTIRIDINES AND 3-CIANO-1,7-NAFTIRIDINS AS INHIBITORS OF PROTEIN KINASES|

---

WO2001083432A2|2000-05-02|2001-11-08|Array Biopharma, Inc.|Process for the reduction of cyano-substituted sulfones to aminoalkylene-substituted sulfones|

---

OA12291A|2000-06-22|2004-03-18|Pfizer Prod Inc|Substituted bicyclic derivatives for the treatmentof abnormal cell growth.|

---

CN1267431C|2000-06-28|2006-08-02|阿斯特拉曾尼卡有限公司|Substituted quinazoline derivatives and their use as inhibitors|

---

EP1792902A1|2000-06-30|2007-06-06|Glaxo Group Limited|Processes for preparation of 5--furan-2-carbaldehydes|

---

JP4102185B2|2000-06-30|2008-06-18|グラクソグループリミテッド|Quinazoline ditosylate compound|

---

JP2004505964A|2000-08-09|2004-02-26|アストラゼネカ　アクチボラグ|Quinoline derivatives having VEGF inhibitory activity|

---

US7829566B2|2001-09-17|2010-11-09|Werner Mederski|4-amino-quinazolines|

---

EP1318984A1|2000-09-20|2003-06-18|MERCK PATENT GmbH|4-amino-quinazolines|

---

TWI304061B|2000-10-20|2008-12-11|Eisai R&D Man Co Ltd|Nitrogen-containing aromatic ring derivatives|

---

US7776315B2|2000-10-31|2010-08-17|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Pharmaceutical compositions based on anticholinergics and additional active ingredients|

---

EP1337524A1|2000-11-02|2003-08-27|AstraZeneca AB|Substituted quinolines as antitumor agents|

---

JP2004517059A|2000-11-02|2004-06-10|アストラゼネカアクチボラグ|4-Substituted quinolines for antitumor agents|

---

US7019012B2|2000-12-20|2006-03-28|Boehringer Ingelheim International Pharma Gmbh & Co. Kg|Quinazoline derivatives and pharmaceutical compositions containing them|

---

ME00502B|2001-01-05|2011-10-10|Amgen Fremont Inc|Antibodies to insulin-like growth factor i receptor|

---

EP1512413A3|2001-01-16|2009-09-23|Glaxo Group Limited|Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer|

---

WO2002056912A2|2001-01-16|2002-07-25|Glaxo Group Limited|Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent|

---

AU2002252338B2|2001-03-15|2007-09-13|Rhode Island Hospital, A Lifespan Partner|Taurine compounds|

---

PE20020958A1|2001-03-23|2002-11-14|Bayer Corp|RHO-KINASE INHIBITORS|

---

MY134783A|2001-03-23|2007-12-31|Bayer Healthcare Llc|Rho-kinase inhibitors|

---

ES2263743T3|2001-04-13|2006-12-16|Pfizer Products Inc.|DERIVATIVES OF 4-AMINOPIRIDOPIRIMIDINE REPLACED WITH A BICYCLE GROUP.|

---

WO2002092578A1|2001-05-14|2002-11-21|Astrazeneca Ab|Quinazoline derivatives|

---

US6995171B2|2001-06-21|2006-02-07|Agouron Pharmaceuticals, Inc.|Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents|

---

US20090197852A9|2001-08-06|2009-08-06|Johnson Robert G Jr|Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor|

---

AR039067A1|2001-11-09|2005-02-09|Pfizer Prod Inc|ANTIBODIES FOR CD40|

---

JP4505228B2|2002-01-10|2010-07-21|バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト|Rho-kinase inhibitor|

---

BR0306982A|2002-01-17|2004-10-26|Neurogen Corp|Compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, methods to reduce the calcium conductance of a cell capsaicin receptor, to inhibit the binding of vanilloid ligand to a capsaicin receptor in vitro and in a patient, to treat a condition responsive to modulation of the capsaicin receptor in a patient, to treat pain in a patient, to treat itching in a patient, to treat coughing or hiccups in a patient, to promote weight loss in an obese patient, and to determine the presence or absence capsaicin receptor in a sample, packaged pharmaceutical preparation, and use of a compound|

---

CA2473910C|2002-01-23|2011-03-15|Bayer Pharmaceuticals Corporation|Pyrimidine derivatives as rho-kinase inhibitors|

---

US6924290B2|2002-01-23|2005-08-02|Bayer Pharmaceuticals Corporation|Rho-kinase inhibitors|

---

NZ534171A|2002-02-01|2007-06-29|Astrazeneca Ab|Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability|

---

EP1481971B1|2002-02-06|2011-11-16|Ube Industries, Ltd.|Process for producing 4-aminoquinazoline compound|

---

EP1492568A1|2002-04-08|2005-01-05|SmithKline Beecham Corporation|Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor|

---

DE10221018A1|2002-05-11|2003-11-27|Boehringer Ingelheim Pharma|Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia/ prostatic hypertrophy|

---

JPWO2003101491A1|2002-06-03|2005-09-29|三菱ウェルファーマ株式会社|Prophylactic and / or therapeutic agent for Her2 or / and EGFR expression or activation target|

---

BR0311806A|2002-06-14|2005-03-29|Pfizer|Benzocondensate heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including them and methods for their use|

---

GB0215823D0|2002-07-09|2002-08-14|Astrazeneca Ab|Quinazoline derivatives|

---

WO2004004732A1|2002-07-09|2004-01-15|Astrazeneca Ab|Quinazoline derivatives for use in the treatment of cancer|

---

US20040048887A1|2002-07-09|2004-03-11|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors|

---

EP1521747B1|2002-07-15|2018-09-05|Symphony Evolution, Inc.|Receptor-type kinase modulators and methods of use|

---

GB0225579D0|2002-11-02|2002-12-11|Astrazeneca Ab|Chemical compounds|

---

US8505468B2|2002-11-19|2013-08-13|Sharp Kabushiki Kaisha|Substrate accommodating tray|

---

US20040156869A1|2002-12-13|2004-08-12|Neurogen Corporation|2-substituted quinazolin-4-ylamine analogues|

---

DK1585743T3|2002-12-19|2007-09-17|Pfizer|2--benzamide compounds as protein kinase inhibitors, useful for treating ophthalmic diseases|

---

AU2003292435A1|2002-12-23|2004-07-14|Astrazeneca Ab|4--quinazoline derivatives as anti-tumor agents|

---

WO2004060400A1|2003-01-06|2004-07-22|Mitsubishi Pharma Corp|Antipsychotic molecular-targeting epithelial growth factor receptor|

---

US7223749B2|2003-02-20|2007-05-29|Boehringer Ingelheim International Gmbh|Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them|

---

AP2114A|2003-02-26|2010-03-04|Sugen Inc|Aminoheteroaryl compounds as protein kinase inhibitors|

---

GB0304367D0|2003-02-26|2003-04-02|Pharma Mar Sau|Methods for treating psoriasis|

---

EP1633870B1|2003-05-30|2013-03-27|OncoTherapy Science, Inc.|Process for screening a drug response in cancer patients|

---

TW200510373A|2003-07-14|2005-03-16|Neurogen Corp|Substituted quinolin-4-ylamine analogues|

---

US7329664B2|2003-07-16|2008-02-12|Neurogen Corporation|Substituted -methanol analogues|

---

NZ544797A|2003-07-18|2011-04-29|Amgen Fremont Inc|Specific antibodies that bind HGF and neutralise binding of HGF to met|

---

WO2005011607A2|2003-08-01|2005-02-10|Smithkline Beecham Corporation|Treatment of cancers expressing p95 erbb2|

---

JP2007504122A|2003-08-29|2007-03-01|ファイザー・インク|Thienopyridine-phenylacetamide and its derivatives useful as novel anti-angiogenic agents|

---

GB0321066D0|2003-09-09|2003-10-08|Pharma Mar Sau|New antitumoral compounds|

---

AR045563A1|2003-09-10|2005-11-02|Warner Lambert Co|ANTIBODIES DIRECTED TO M-CSF|

---

CA2744997A1|2003-09-26|2005-04-07|Exelixis, Inc.|C-met modulators and method of use|

---

DE10349113A1|2003-10-17|2005-05-12|Boehringer Ingelheim Pharma|Process for the preparation of aminocrotonyl compounds|

---

JP2007510667A|2003-11-07|2007-04-26|スミスクラインビーチャム（コーク）リミテッド|Cancer treatment|

---

WO2005044788A1|2003-11-11|2005-05-19|Eisai Co., Ltd.|Urea derivative and process for producing the same|

---

GB0326459D0|2003-11-13|2003-12-17|Astrazeneca Ab|Quinazoline derivatives|

---

WO2005058913A1|2003-12-18|2005-06-30|Janssen Pharmaceutica N.V.|Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents|

---

GB0330002D0|2003-12-24|2004-01-28|Astrazeneca Ab|Quinazoline derivatives|

---

WO2005105094A2|2004-04-16|2005-11-10|Smithkline Beecham Corporation|Cancer treatment method|

---

WO2005107758A1|2004-05-06|2005-11-17|Warner-Lambert Company Llc|4-phenylamino-quinazolin-6-yl-amides|

---

EP1768963A4|2004-06-03|2009-06-10|Smithkline Beecham Cork Ltd|Cancer treatment method|

---

CN1984656B|2004-06-04|2010-05-26|史密丝克莱恩比彻姆（科克）有限公司|Cancer treatment method|

---

WO2005120509A1|2004-06-04|2005-12-22|Amphora Discovery Corporation|Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof|

---

EP1765313A2|2004-06-24|2007-03-28|Novartis Vaccines and Diagnostics, Inc.|Compounds for immunopotentiation|

---

US20100226931A1|2004-06-24|2010-09-09|Nicholas Valiante|Compounds for immunopotentiation|

---

US20060035893A1|2004-08-07|2006-02-16|Boehringer Ingelheim International Gmbh|Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders|

---

UA87153C2|2004-08-26|2009-06-25|Пфайзер Инк.|Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors|

---

ES2322175T3|2004-09-17|2009-06-17|EISAI R&amp;D MANAGEMENT CO., LTD.|MEDICINAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELIFICATION.|

---

TW200621251A|2004-10-12|2006-07-01|Neurogen Corp|Substituted biaryl quinolin-4-ylamine analogues|

---

US7652009B2|2004-11-30|2010-01-26|Amgem Inc.|Substituted heterocycles and methods of use|

---

GB0427131D0|2004-12-10|2005-01-12|Glaxosmithkline Biolog Sa|Novel combination|

---

JP4881875B2|2004-12-14|2012-02-22|アストラゼネカアクチボラグ|Pyrazolopyrimidine compounds as antitumor agents|

---

CN101083995A|2004-12-17|2007-12-05|史密丝克莱恩比彻姆（科克）有限公司|Cancer treatment method|

---

EP1828185B1|2004-12-21|2009-05-06|SmithKline Beecham Corporation|2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors|

---

US7812022B2|2004-12-21|2010-10-12|Glaxosmithkline Llc|2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors|

---

PE20060777A1|2004-12-24|2006-10-06|Boehringer Ingelheim Int|INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES|

---

WO2006076646A2|2005-01-14|2006-07-20|Neurogen Corporation|Heteroaryl substituted quinolin-4-ylamine analogues|

---

US8735394B2|2005-02-18|2014-05-27|Abraxis Bioscience, Llc|Combinations and modes of administration of therapeutic agents and combination therapy|

---

WO2006089290A1|2005-02-18|2006-08-24|Abraxis Bioscience Inc..|Combinations and modes of administration of therapeutic agents and combination therapy|

---

US20060216288A1|2005-03-22|2006-09-28|Amgen Inc|Combinations for the treatment of cancer|

---

EP1863848A4|2005-03-31|2009-09-23|Agensys Inc|Antibodies and related molecules that bind to 161p2f10b proteins|

---

TW200716204A|2005-04-19|2007-05-01|Smithkline Beecham Cork Ltd|Pharmaceutical composition|

---

BRPI0608096A2|2005-04-26|2009-11-10|Pfizer|p-cadherin antibodies|

---

EP2281901B1|2005-08-02|2013-11-27|Eisai R&D Management Co., Ltd.|Anti-tumour pharmaceutical composition with angiogenesis inhibitors|

---

US7537762B2|2005-09-07|2009-05-26|Amgen Fremont, Inc.|Human monoclonal antibodies to activin receptor-like kinase-1|

---

EP1926996B1|2005-09-20|2011-11-09|OSI Pharmaceuticals, Inc.|Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors|

---

WO2007034144A1|2005-09-20|2007-03-29|Astrazeneca Ab|4- -quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer|

---

SG173408A1|2005-11-08|2011-08-29|Genentech Inc|Neuropilin antagonists|

---

EP1948179A1|2005-11-11|2008-07-30|Boehringer Ingelheim International GmbH|Quinazoline derivatives for the treatment of cancer diseases|

---

ES2421450T3|2005-12-05|2013-09-02|Glaxosmithkline Llc|ErbB kinase inhibitor pyrimidinyl-pyrazolopyridines|

---

CN101003514A|2006-01-20|2007-07-25|上海艾力斯医药科技有限公司|Derivative of quinazoline, preparation method and usage|

---

JO2660B1|2006-01-20|2012-06-17|نوفارتيس ايه جي|PI-3 Kinase inhibitors and methods of their use|

---

AR059066A1|2006-01-27|2008-03-12|Amgen Inc|COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR |

---

CN101374840B|2006-01-31|2011-09-28|霍夫曼-拉罗奇有限公司|7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors|

---

PE20070978A1|2006-02-14|2007-11-15|Novartis Ag|HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES |

---

TW200808739A|2006-04-06|2008-02-16|Novartis Vaccines & Diagnostic|Quinazolines for PDK1 inhibition|

---

US20090203718A1|2006-04-13|2009-08-13|Smithkline BeechamLtd.|Cancer treatment method|

---

CN101472915A|2006-04-19|2009-07-01|诺瓦提斯公司|Indazole compounds and methods for inhibition of CDC7|

---

EP2021338A1|2006-05-09|2009-02-11|Pfizer Products Inc.|Cycloalkylamino acid derivatives and pharmaceutical compositions thereof|

---

NL2000613C2|2006-05-11|2007-11-20|Pfizer Prod Inc|Triazole pyrazine derivatives.|

---

AU2007252506C1|2006-05-18|2012-07-19|Eisai R & D Management Co., Ltd.|Antitumor agent for thyroid cancer|

---

ES2318616T3|2006-06-01|2009-05-01|Cellzome Ag|METHODS FOR THE IDENTIFICATION OF MOLECULES THAT INTERACT WITH ZAP-70 AND FOR THE PURIFICATION OF ZAP-70.|

---

ES2427924T3|2006-06-30|2013-11-04|Merck Sharp & Dohme Corp.|IGFBP2 biomarker|

---

PE20080403A1|2006-07-14|2008-04-25|Amgen Inc|FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE|

---

US8217177B2|2006-07-14|2012-07-10|Amgen Inc.|Fused heterocyclic derivatives and methods of use|

---

US20110053964A1|2006-08-22|2011-03-03|Roger Tung|4-aminoquinazoline derivatives and methods of use thereof|

---

AU2007288204A1|2006-08-22|2008-02-28|Concert Pharmaceuticals Inc.|4-aminoquinazoline derivatives and methods of use thereof|

---

WO2008026748A1|2006-08-28|2008-03-06|Eisai R & D Management Co., Ltd.|Antitumor agent for undifferentiated gastric cancer|

---

NZ576065A|2006-09-18|2011-12-22|Boehringer Ingelheim Int|Method for treating cancer harboring egfr mutations|

---

MX2009003673A|2006-10-04|2009-04-22|Pfizer Prod Inc|Pyrido[4,3-d]pyrimidin-4-one derivatives as calcium receptor antagonists.|

---

US8916552B2|2006-10-12|2014-12-23|Astex Therapeutics Limited|Pharmaceutical combinations|

---

JP5528807B2|2006-10-12|2014-06-25|アステックス、セラピューティックス、リミテッド|Compound drug|

---

WO2008054633A1|2006-10-31|2008-05-08|Janssen Pharmaceutica N.V.|Hydrazone derivatives as kinase inhibitors|

---

WO2008063888A2|2006-11-22|2008-05-29|Plexxikon, Inc.|Compounds modulating c-fms and/or c-kit activity and uses therefor|

---

JP2010513278A|2006-12-13|2010-04-30|シェーリングコーポレイション|Method for treating cancer using IGF1R inhibitor|

---

US7687522B2|2006-12-20|2010-03-30|Amgen Inc.|Substituted pyridines and pyrimidines and their use in treatment of cancer|

---

WO2008086014A2|2007-01-09|2008-07-17|Amgen Inc.|Bis-aryl amide derivatives useful for the treatment of cancer|

---

AU2008211952B2|2007-01-29|2012-07-19|Eisai R & D Management Co., Ltd.|Composition for treatment of undifferentiated-type of gastric cancer|

---

CN101245050A|2007-02-14|2008-08-20|上海艾力斯医药科技有限公司|4-aniline quinazoline derivative salt|

---

MX2009008531A|2007-02-16|2009-08-26|Amgen Inc|Nitrogen-containing heterocyclyl ketones and methods of use.|

---

US8715665B2|2007-04-13|2014-05-06|The General Hospital Corporation|Methods for treating cancer resistant to ErbB therapeutics|

---

EP2155716A2|2007-05-09|2010-02-24|Pfizer Inc.|Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials|

---

US20110245496A1|2007-06-11|2011-10-06|Andrew Simon Craig|Quinazoline Salt Compounds|

---

UY31137A1|2007-06-14|2009-01-05|Smithkline Beecham Corp|DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THE PI3 QUINASA|

---

PT2188313T|2007-08-21|2017-12-12|Amgen Inc|Human c-fms antigen binding proteins|

---

ES2424745T3|2007-09-07|2013-10-08|Agensys, Inc.|Antibodies and related molecules that bind to 24P4C12 proteins|

---

US20090215802A1|2007-09-13|2009-08-27|Protia, Llc|Deuterium-enriched lapatinib|

---

CN101861159A|2007-10-19|2010-10-13|马尔药品公司|Improved antitumoral treatments|

---

MX2010004327A|2007-10-22|2010-05-13|Schering Corp|Fully human anti-vegf antibodies and methods of using.|

---

JP2011502141A|2007-10-29|2011-01-20|ナトコファーマリミテッド|4--quinazoline derivatives as anticancer agents|

---

AU2008325608B2|2007-11-09|2013-03-14|Eisai R & D Management Co., Ltd.|Combination of anti-angiogenic substance and anti-tumor platinum complex|

---

CN101952282A|2007-12-20|2011-01-19|诺瓦提斯公司|Thiazole derivatives used as PI 3 kinase inhibitors|

---

CN101492445A|2008-01-22|2009-07-29|孙飘扬|Heteroaromatic compound, preparation method and uses thereof|

---

JP2011515330A|2008-01-30|2011-05-19|ファルマ・マール・ソシエダード・アノニマ|Improved antitumor treatment|

---

AU2009221120A1|2008-03-07|2009-09-11|Pharma Mar, S.A.|Improved antitumoral treatments|

---

WO2009117277A2|2008-03-18|2009-09-24|Genentech, Inc.|Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use|

---

US8252805B2|2008-05-07|2012-08-28|Teva Pharmaceutical Industries Ltd.|Forms of lapatinib ditosylate and processes for preparation thereof|

---

US20090306106A1|2008-05-15|2009-12-10|Leonid Metsger|Forms of crystalline lapatinib and processes for preparation thereof|

---

CN101584696A|2008-05-21|2009-11-25|上海艾力斯医药科技有限公司|Composition containing quinazoline derivatives, preparation method and use|

---

US20100197915A1|2008-08-06|2010-08-05|Leonid Metsger|Lapatinib intermediates|

---

EP2158913A1|2008-08-25|2010-03-03|Ratiopharm GmbH|Pharmaceutical composition comprising N-[3-chhloro-4-[methoxy]phenyl]6-ethyl]amino]methyl]-2-furyl]-4-quinazolinamine|

---

EP2158912A1|2008-08-25|2010-03-03|Ratiopharm GmbH|Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-ethyl]amino]methyl]-2-furyl]-4-quinazolinamine|

---

US20100087459A1|2008-08-26|2010-04-08|Leonid Metsger|Forms of lapatinib compounds and processes for the preparation thereof|

---

US8476410B2|2008-10-16|2013-07-02|University of Pittsburgh—of the Commonwealth System of Higher Education|Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof|

---

WO2010061400A1|2008-11-03|2010-06-03|Natco Pharma Limited|A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts|

---

EP2349235A1|2008-11-07|2011-08-03|Triact Therapeutics, Inc.|Use of catecholic butane derivatives in cancer therapy|

---

MX2011007620A|2009-01-16|2011-11-04|Exelixis Inc|Malate salt of n-quin0lin-4-yl] oxy}phenyl)-n' -cyclopropane-1,1-dicarboxamid e, and crystalline forms therof for the treatment of cancer.|

---

CN101787017A|2009-01-23|2010-07-28|岑均达|Optical pure quinazoline compound|

---

WO2010090764A1|2009-02-09|2010-08-12|Supergen, Inc.|Pyrrolopyrimidinyl axl kinase inhibitors|

---

US20120189641A1|2009-02-25|2012-07-26|OSI Pharmaceuticals, LLC|Combination anti-cancer therapy|

---

US20110171124A1|2009-02-26|2011-07-14|Osi Pharmaceuticals, Inc.|In situ methodsfor monitoring the EMT status of tumor cells in vivo|

---

WO2010099138A2|2009-02-27|2010-09-02|Osi Pharmaceuticals, Inc.|Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation|

---

US8642834B2|2009-02-27|2014-02-04|OSI Pharmaceuticals, LLC|Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation|

---

TW201035088A|2009-02-27|2010-10-01|Supergen Inc|Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors|

---

JP2012519282A|2009-02-27|2012-08-23|オーエスアイ・ファーマシューティカルズ，エルエルシー|Methods for identifying mesenchymal tumor cells or agents that inhibit their production|

---

WO2010101734A1|2009-03-06|2010-09-10|Merck Sharp & Dohme Corp.|Combination cancer therapy with an akt inhibitor and other anticancer agents|

---

US20120064072A1|2009-03-18|2012-03-15|Maryland Franklin|Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor|

---

KR20150036824A|2009-03-20|2015-04-07|제넨테크, 인크.|Bispecific anti-her antibodies|

---

WO2011121317A1|2010-04-01|2011-10-06|Centro Nacional De Investigaciones Oncologicas |Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors|

---

WO2010120388A1|2009-04-17|2010-10-21|Nektar Therapeutics|Oligomer-protein tyrosine kinase inhibitor conjugates|

---

US8530492B2|2009-04-17|2013-09-10|Nektar Therapeutics|Oligomer-protein tyrosine kinase inhibitor conjugates|

---

US8293753B2|2009-07-02|2012-10-23|Novartis Ag|Substituted 2-carboxamide cycloamino ureas|

---

ES2731901T3|2009-07-06|2019-11-19|Boehringer Ingelheim Int|Process for drying BIBW2992, its salts and solid pharmaceutical formulations comprising this active ingredient|

---

GEP20156310B|2009-08-07|2015-07-10|Exelixis Inc|Methods of using c-met modulators|

---

DK2467140T3|2009-08-21|2016-09-05|Novartis Ag|Lapatinib for the treatment of cancer|

---

CA2772194A1|2009-09-01|2011-03-10|Pfizer Inc.|Benzimidazole derivatives|

---

JP2013505899A|2009-09-28|2013-02-21|チールーファーマシューティカルカンパニー、リミテッド|4-quinazoline derivatives useful as tyrosine kinase inhibitors|

---

WO2011039759A1|2009-09-29|2011-04-07|Natco Pharma Limited|A new process for the preparation of lapatinib and its pharmaceutically acceptable salts|

---

US20120316187A1|2009-11-13|2012-12-13|Pangaea Biotech, S.L.|Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer|

---

CN102079759B|2009-12-01|2014-09-17|天津药物研究院|6-substituted quinazoline derivative, preparation method and application thereof|

---

US20110165155A1|2009-12-04|2011-07-07|Genentech, Inc.|Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1|

---

AU2010338038B2|2009-12-31|2015-07-09|Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii|Tricyclic compounds for use as kinase inhibitors|

---

CA2787714C|2010-01-22|2019-04-09|Joaquin Pastor Fernandez|Inhibitors of pi3 kinase|

---

US8754072B2|2010-02-12|2014-06-17|Pfizer Inc.|Salts and polymorphs of 8-fluoro-2-{4-[methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one|

---

SG183361A1|2010-02-18|2012-09-27|Ct Nac Investigaciones Oncologicas Cnio|Triazolo [4, 5 - b] pyridin derivatives|

---

WO2011109572A2|2010-03-03|2011-09-09|OSI Pharmaceuticals, LLC|Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors|

---

EP2542893A2|2010-03-03|2013-01-09|OSI Pharmaceuticals, LLC|Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors|

---

KR101718578B1|2010-03-23|2017-03-21|시노팜 타이완 리미티드|Process and intermediates for preparing lapatinib|

---

US8710221B2|2010-03-23|2014-04-29|Scinopharm Taiwan, Ltd.|Process and intermediates for preparing lapatinib|

---

KR20190109593A|2010-03-29|2019-09-25|아브락시스 바이오사이언스, 엘엘씨|Methods of enhancing drug delivery and effectiveness of therapeutic agents|

---

KR101894689B1|2010-03-29|2018-09-04|아브락시스 바이오사이언스, 엘엘씨|Methods of treating cancer|

---

EP2571358B1|2010-05-21|2015-01-07|GlaxoSmithKline LLC|Combination therapy for treating cancer|

---

US20130072507A1|2010-05-21|2013-03-21|Glaxosmithkline Llc|Combination|

---

NZ604031A|2010-06-04|2015-05-29|Abraxis Bioscience Llc|Methods of treatment of pancreatic cancer|

---

EP3135692B8|2010-06-16|2019-03-20|University of Pittsburgh - Of the Commonwealth System of Higher Education|Antibodies to endoplasmin and their use|

---

WO2011161217A2|2010-06-23|2011-12-29|Palacký University in Olomouc|Targeting of vegfr2|

---

RU2560683C2|2010-06-25|2015-08-20|Эйсай Ар Энд Ди Менеджмент Ко., Лтд.|Anticancer agent involving combinations of kinase inhibitory compounds|

---

RU2571226C2|2010-07-09|2015-12-20|Дженентек, Инк.|Antibodies against neyropilin and methods of their application|

---

CN102344444B|2010-07-23|2015-07-01|岑均达|Optically pure quinazoline compounds|

---

CN102344445B|2010-07-23|2015-11-25|岑均达|Optical pure quinazoline compound|

---

AR082418A1|2010-08-02|2012-12-05|Novartis Ag|CRYSTAL FORMS OF 1--PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID-PIRROLIDIN-1,2-DICARBOXILICO|

---

US20120089541A1|2010-08-31|2012-04-12|Genentech, Inc.|Biomarkers and methods of treatment|

---

WO2012052948A1|2010-10-20|2012-04-26|Pfizer Inc.|Pyridine- 2- derivatives as smoothened receptor modulators|

---

WO2012052745A1|2010-10-21|2012-04-26|Centro Nacional De Investigaciones Oncológicas |Combinations of pi3k inhibitors with a second anti -tumor agent|

---

US20130236467A1|2010-11-24|2013-09-12|Jeremy Griggs|Multispecific antigen binding proteins targeting hgf|

---

CN102558160B|2010-12-20|2015-09-23|天津药物研究院|4-replaces Toluidrin anilino-quinazoline derivatives and its production and use|

---

CN102558159A|2010-12-20|2012-07-11|天津药物研究院|4-subsittution m sulfonylurea amide aniline-quinazoline derivate and preparation method and application thereof|

---

EP2468883A1|2010-12-22|2012-06-27|Pangaea Biotech S.L.|Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer|

---

CA2822923A1|2010-12-23|2012-06-28|Apotex Pharmachem Inc.|A process for the preparation of lapatinib and its ditosylate salt|

---

US9134297B2|2011-01-11|2015-09-15|Icahn School Of Medicine At Mount Sinai|Method and compositions for treating cancer and related methods|

---

WO2012098387A1|2011-01-18|2012-07-26|Centro Nacional De Investigaciones Oncológicas |6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors|

---

BR112013019509A2|2011-01-31|2017-03-28|Novartis Ag|heterocyclic derivatives|

---

US20120214830A1|2011-02-22|2012-08-23|OSI Pharmaceuticals, LLC|Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma|

---

EP2492688A1|2011-02-23|2012-08-29|Pangaea Biotech, S.A.|Molecular biomarkers for predicting response to antitumor treatment in lung cancer|

---

JP6026441B2|2011-03-04|2016-11-16|グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ|Aminoquinolines as kinase inhibitors|

---

MX344302B|2011-03-04|2016-12-13|Newgen Therapeutics Inc|Alkyne substituted quinazoline compound and methods of use.|

---

CA2829219C|2011-03-09|2021-03-16|Richard G. Pestell|Prostate cancer cell lines, gene signatures and uses thereof|

---

WO2012125904A1|2011-03-17|2012-09-20|The Trustees Of The University Of Pennsylvania|Mutation mimicking compounds that bind to the kinase domain of egfr|

---

CN103648500B|2011-03-17|2016-05-04|宾夕法尼亚大学理事会|Method and the purposes of bifunctional enzyme pincers type processed molecule|

---

WO2012129145A1|2011-03-18|2012-09-27|OSI Pharmaceuticals, LLC|Nscle combination therapy|

---

WO2012129344A1|2011-03-23|2012-09-27|Amgen Inc.|Fused tricyclic dual inhibitors of cdk 4/6 and flt3|

---

EP2694070A4|2011-04-01|2014-09-03|Genentech Inc|Combinations of akt inhibitor compounds and erlotinib, and methods of use|

---

US9150644B2|2011-04-12|2015-10-06|The United States Of America, As Represented By The Secretary, Department Of Health And Human Services|Human monoclonal antibodies that bind insulin-like growth factorI and II|

---

CA2828946C|2011-04-18|2016-06-21|Eisai R&D Management Co., Ltd.|Therapeutic agent for tumor|

---

WO2012145183A2|2011-04-19|2012-10-26|Pfizer Inc.|Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer|

---

WO2012149014A1|2011-04-25|2012-11-01|OSI Pharmaceuticals, LLC|Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment|

---

WO2012155339A1|2011-05-17|2012-11-22|江苏康缘药业股份有限公司|4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof|

---

EP2524918A1|2011-05-19|2012-11-21|Centro Nacional de Investigaciones Oncológicas |Imidazopyrazines derivates as kinase inhibitors|

---

BR112013029711B1|2011-05-19|2020-05-12|Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii|COMPOUNDS|

---

ITMI20110894A1|2011-05-20|2012-11-21|Italiana Sint Spa|IMPACT OF THE LAPATINIB AND ITS SALTS|

---

JP5414739B2|2011-05-25|2014-02-12|三菱電機株式会社|Semiconductor test jig|

---

EP2714937B1|2011-06-03|2018-11-14|Eisai R&D Management Co., Ltd.|Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds|

---

WO2013005041A1|2011-07-07|2013-01-10|Centro Nacional De Investigaciones Oncológicas |Tricyclic heterocyclic compounds as kinase inhibitors|

---

WO2013005057A1|2011-07-07|2013-01-10|Centro Nacional De Investigaciones Oncológicas |New compounds|

---

WO2013004984A1|2011-07-07|2013-01-10|Centro Nacional De Investigaciones Oncologicas |Tricyclic compounds for use as kinase inhibitors|

---

WO2013013188A1|2011-07-21|2013-01-24|Tolero Pharmaceuticals, Inc.|Heterocyclic protein kinase inhibitors|

---

US9499530B2|2011-08-01|2016-11-22|Hangzhou Minsheng Institutes For Pharma Research|Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament|

---

US9745288B2|2011-08-16|2017-08-29|Indiana University Research And Technology Corporation|Compounds and methods for treating cancer by inhibiting the urokinase receptor|

---

TWI547494B|2011-08-18|2016-09-01|葛蘭素史克智慧財產發展有限公司|Amino quinazolines as kinase inhibitors|

---

WO2013033380A1|2011-08-31|2013-03-07|Genentech, Inc.|Diagnostic markers|

---

BR112014006840A2|2011-09-22|2017-04-04|Pfizer|pyrrolopyrimidine and purine derivatives|

---

EP2761025A1|2011-09-30|2014-08-06|Genentech, Inc.|Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells|

---

US9783613B2|2011-10-04|2017-10-10|Igem Therapeutics Limited|IgE anti-HMW-MAA antibody|

---

ES2587533T3|2011-10-28|2016-10-25|Novartis Ag|Purine derivatives and their use in the treatment of diseases|

---

BR112014011115A2|2011-11-08|2017-06-13|Pfizer|Methods for treating inflammatory disorders using anti-csf antibodies|

---

WO2013080218A1|2011-11-28|2013-06-06|Fresenius Kabi Oncology Ltd.|Novel intermediates and process for the preparation of lapatinib and its pharmaceutically acceptable salts|

---

WO2013113796A1|2012-01-31|2013-08-08|Smithkline BeechamLimited|Method of treating cancer|

---

AR090263A1|2012-03-08|2014-10-29|Hoffmann La Roche|COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME|

---

KR102115047B1|2012-04-03|2020-05-26|노파르티스 아게|Combination products with tyrosine kinase inhibitors and their use|

---

WO2013152252A1|2012-04-06|2013-10-10|OSI Pharmaceuticals, LLC|Combination anti-cancer therapy|

---

JP6518585B2|2012-05-14|2019-05-22|リチャード ジー． ペステル|Use of CCR5 Modifiers for the Treatment of Cancer|

---

RU2630975C2|2012-05-16|2017-09-15|Новартис Аг|Pi-3 kinase dosage regime|

---

WO2013190089A1|2012-06-21|2013-12-27|Pangaea Biotech, S.L.|Molecular biomarkers for predicting outcome in lung cancer|

---

EP2890696A1|2012-08-29|2015-07-08|Amgen, Inc.|Quinazolinone compounds and derivatives thereof|

---

TWI592417B|2012-09-13|2017-07-21|葛蘭素史克智慧財產發展有限公司|Prodrugs of amino quinazoline kinase inhibitor|

---

WO2014062838A2|2012-10-16|2014-04-24|Tolero Pharmaceuticals, Inc.|Pkm2 modulators and methods for their use|

---

CZ2012712A3|2012-10-17|2014-04-30|Zentiva, K.S.|Novel process for preparing key intermediate for the preparation of lapatinib o|

---

CN102942561A|2012-11-06|2013-02-27|深圳海王药业有限公司|4-amino quinazoline heterocyclic compound and purpose of 4-amino quinazoline heterocyclic compound|

---

US9260426B2|2012-12-14|2016-02-16|Arrien Pharmaceuticals Llc|Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2inhibitors|

---

WO2014098176A1|2012-12-21|2014-06-26|エーザイ・アール・アンド・ディー・マネジメント株式会社|Amorphous form of quinoline derivative, and method for producing same|

---

CN103896889B|2012-12-27|2016-05-25|上海创诺制药有限公司|Lapatinib intermediate and its preparation method and application|

---

US9353122B2|2013-02-15|2016-05-31|Kala Pharmaceuticals, Inc.|Therapeutic compounds and uses thereof|

---

WO2014128107A1|2013-02-19|2014-08-28|Hexal Ag|Pharmaceutical composition comprising n-[3-chloro-4-phenyl]-6-[5ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof|

---

US9890173B2|2013-11-01|2018-02-13|Kala Pharmaceuticals, Inc.|Crystalline forms of therapeutic compounds and uses thereof|

---

US9688688B2|2013-02-20|2017-06-27|Kala Pharmaceuticals, Inc.|Crystalline forms of 4-oxy)-6-methoxyquinazolin-7-yl)oxy)-1-butan-1-one and uses thereof|

---

CN107915751A|2013-02-20|2018-04-17|卡拉制药公司|Therapeutic compound and its purposes|

---

WO2014128622A1|2013-02-21|2014-08-28|Glaxosmithkline Intellectual Property Development Limited|Quinazolines as kinase inhibitors|

---

EP2958592A1|2013-02-22|2015-12-30|F.Hoffmann-La Roche Ag|Methods of treating cancer and preventing drug resistance|

---

CN103159747A|2013-02-26|2013-06-19|常州鸿创高分子科技有限公司|Synthetic method of lapatinib|

---

WO2014134202A1|2013-02-26|2014-09-04|Triact Therapeutics, Inc.|Cancer therapy|

---

CN105246511A|2013-03-06|2016-01-13|豪夫迈·罗氏有限公司|Methods of treating and preventing cancer drug resistance|

---

KR20150127216A|2013-03-14|2015-11-16|제넨테크, 인크.|Methods of treating cancer and preventing cancer drug resistance|

---

WO2014151871A2|2013-03-14|2014-09-25|Tolero Pharmaceuticals, Inc.|Jak2 and alk2 inhibitors and methods for their use|

---

MX2015011899A|2013-03-15|2016-05-05|Genentech Inc|Methods of treating cancer and preventing cancer drug resistance.|

---

EP2976085A1|2013-03-21|2016-01-27|INSERM - Institut National de la Santé et de la Recherche Médicale|Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression|

---

WO2014170910A1|2013-04-04|2014-10-23|Natco Pharma Limited|Process for the preparation of lapatinib|

---

US9206188B2|2013-04-18|2015-12-08|Arrien Pharmaceuticals Llc|Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors|

---

NZ714049A|2013-05-14|2020-05-29|Eisai R&D Man Co Ltd|Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds|

---

HU231012B1|2013-05-24|2019-11-28|Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság|Lapatinib salts|

---

CN105705494B|2013-07-18|2017-12-15|锦州奥鸿药业有限责任公司|Quinazoline derivant and its pharmaceutical composition, and the purposes as medicine|

---

EP3044593A4|2013-09-09|2017-05-17|Triact Therapeutics, Inc.|Cancer therapy|

---

JP6946000B2|2013-10-04|2021-10-06|アプトース バイオサイエンシーズ， インコーポレイテッド|Compositions and Methods for the Treatment of Cancer|

---

CA2928658A1|2013-11-01|2015-05-07|Kala Pharmaceuticals, Inc.|Crystalline forms of therapeutic compounds and uses thereof|

---

CN103554091B|2013-11-05|2016-05-18|沈阳工业大学|Quinazoline derivant and its production and use|

---

HUE039858T2|2013-11-21|2019-02-28|Pfizer|2,6-substituted purine derivatives and their use in the treatment of proliferative disorders|

---

US9242965B2|2013-12-31|2016-01-26|Boehringer Ingelheim International Gmbh|Process for the manufacture of -4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors|

---

SG10202000191YA|2014-01-24|2020-03-30|Turning Point Therapeutics Inc|Diaryl macrocycles as modulators of protein kinases|

---

US20160361309A1|2014-02-26|2016-12-15|Glaxosmithkline Intellectual PropertyLimited|Methods of treating cancer patients responding to ezh2 inhibitor gsk126|

---

KR20160137599A|2014-03-24|2016-11-30|제넨테크, 인크.|Cancer treatment with c-met antagonists and correlation of the latter with hgf expression|

---

WO2015155624A1|2014-04-10|2015-10-15|Pfizer Inc.|Dihydropyrrolopyrimidine derivatives|

---

US20170027940A1|2014-04-10|2017-02-02|Stichting Het Nederlands Kanker Instituut|Method for treating cancer|

---

EP2937346A1|2014-04-24|2015-10-28|F.I.S.- Fabbrica Italiana Sintetici S.p.A.|Co-crystals of lapatinib|

---

ES2759434T3|2014-04-30|2020-05-11|Pfizer|Diheterocycle derivatives bound to cycloalkyl|

---

US9388239B2|2014-05-01|2016-07-12|Consejo Nacional De Investigation Cientifica|Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B|

---

WO2016001789A1|2014-06-30|2016-01-07|Pfizer Inc.|Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer|

---

EP3473271A1|2014-07-31|2019-04-24|The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services|Human monoclonal antibodies against epha4 and their use|

---

JOP20200225A1|2014-08-28|2017-06-16|Eisai R&D Man Co Ltd|Highly pure quinoline derivative and method for producing the same|

---

EP3206717B1|2014-10-17|2020-11-25|Novartis AG|Combination of ceritinib with an egfr inhibitor|

---

KR20200091954A|2014-12-15|2020-07-31|더 리젠츠 오브 더 유니버시티 오브 미시간|Small molecule inhibitors of egfr and pi3k|

---

WO2016097918A1|2014-12-18|2016-06-23|Pfizer Inc.|Pyrimidine and triazine derivatives and their use as axl inhibitors|

---

BR112017012553A2|2014-12-24|2018-07-31|Genentech, Inc.|method of treating a patient suffering from cancer, method for diagnosing a cancer, method for prognosis of a cancer patient, method for determining whether a patient with cancer, and method for optimizing the therapeutic effectiveness of a anticancer therapy|

---

CN105801565B|2014-12-30|2020-04-03|天津法莫西医药科技有限公司|Preparation method of N- [ 3-chloro-4- [methoxy ] phenyl ] -6- [furan-2-yl ] -4-quinazolinamine|

---

CN107517589A|2015-01-08|2017-12-26|小利兰·斯坦福大学托管委员会|The factor and cell of the induction of bone, marrow and cartilage are provided|

---

MA41414A|2015-01-28|2017-12-05|Centre Nat Rech Scient|ICOS AGONIST BINDING PROTEINS|

---

EP3253739A4|2015-02-03|2018-07-18|Trillium Therapeutics Inc.|Novel fluorinated derivatives as egfr inhibitors useful for treating cancers|

---

EP3263106A4|2015-02-25|2018-08-29|Eisai R&D Management Co., Ltd.|Method for suppressing bitterness of quinoline derivative|

---

KR20180018507A|2015-04-20|2018-02-21|톨레로 파마수티컬스, 인크.|Prediction of Response to Albosis Dip by Mitochondrial Profiling|

---

PL3298021T3|2015-05-18|2019-11-29|Tolero Pharmaceuticals Inc|Alvocidib prodrugs having increased bioavailability|

---

CN106279307B|2015-05-19|2019-07-26|正大天晴药业集团股份有限公司|Fragrant ammonia is for glucosan derivative, preparation method and anticancer usage|

---

ES2882255T3|2015-07-01|2021-12-01|California Inst Of Techn|Delivery systems based on cationic mucic acid polymers|

---

MX2017017097A|2015-07-02|2018-05-23|Tp Therapeutics Inc|Chiral diaryl macrocycles as modulators of protein kinases.|

---

WO2017009751A1|2015-07-15|2017-01-19|Pfizer Inc.|Pyrimidine derivatives|

---

JP2018522038A|2015-08-03|2018-08-09|トレロ ファーマシューティカルズ， インコーポレイテッド|Combination therapy for the treatment of cancer|

---

WO2017025871A1|2015-08-07|2017-02-16|Glaxosmithkline Intellectual Property Development Limited|Combination therapy comprising anti ctla-4 antibodies|

---

US11124483B2|2015-09-02|2021-09-21|The Regents Of The University Of California|HER3 ligands and uses thereof|

---

CN106632276B|2015-10-28|2021-06-15|上海天慈生物谷生物工程有限公司|Preparation method of medicine for treating breast cancer|

---

JP2018532750A|2015-11-02|2018-11-08|ノバルティス アーゲー|Dosage regimen of phosphatidylinositol 3-kinase inhibitor|

---

CN108884161A|2015-12-01|2018-11-23|葛兰素史密斯克莱知识产权发展有限公司|Combination therapy and application thereof and method|

---

US20180371551A1|2015-12-03|2018-12-27|Agios Pharmaceuticals, Inc.|Mat2a inhibitors for treating mtap null cancer|

---

MX2018011102A|2016-03-15|2019-01-10|Oryzon Genomics Sa|Combinations of lsd1 inhibitors for use in the treatment of solid tumors.|

---

KR20190034225A|2016-07-28|2019-04-01|티피 테라퓨틱스, 인크.|Macrocyclic kinase inhibitor|

---

EP3494140A1|2016-08-04|2019-06-12|GlaxoSmithKline Intellectual Property Development Ltd|Anti-icos and anti-pd-1 antibody combination therapy|

---

WO2018048747A1|2016-09-08|2018-03-15|Kala Pharmaceuticals, Inc.|Crystalline forms of therapeutic compounds and uses thereof|

---

AU2017324716B2|2016-09-08|2020-08-13|Kala Pharmaceuticals, Inc.|Crystalline forms of therapeutic compounds and uses thereof|

---

CA3036065A1|2016-09-08|2018-03-15|Kala Pharmaceuticals, Inc.|Crystalline forms of therapeutic compounds and uses thereof|

---

WO2018060833A1|2016-09-27|2018-04-05|Novartis Ag|Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib|

---

EP3362471B1|2016-12-19|2021-11-17|Sumitomo Dainippon Pharma Oncology, Inc.|Profiling peptides and methods for sensitivity profiling|

---

PE20191207A1|2016-12-22|2019-09-10|Amgen Inc|BENZOISOTHIAZOLE, ISOTHIAZOLE [3,4-B] PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRID [2,3-D] PYRIDAZINE AND PYRID [2,3-D] PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS TO TREAT PULMON CANCER, PANCREATIC OR COLORRECTAL|

---

SG10201913195RA|2017-05-22|2020-02-27|Amgen Inc|Kras g12c inhibitors and methods of using the same|

---

CA3069232A1|2017-07-28|2019-01-31|Turning Point Therapeutics, Inc.|Macrocyclic compounds and uses thereof|

---

MA50077A|2017-09-08|2020-07-15|Amgen Inc|KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE|

---

US20200237766A1|2017-10-13|2020-07-30|Tolero Pharmaceuticals, Inc.|Pkm2 activators in combination with reactive oxygen species for treatment of cancer|

---

AU2018392332A1|2017-12-19|2020-06-11|Turning Point Therapeutics, Inc.|Macrocyclic compounds for treating disease|

---

JP2021523099A|2018-05-04|2021-09-02|アムジエン・インコーポレーテツド|How to use KRAS G12C inhibitor and the same|

---

EP3788038A1|2018-05-04|2021-03-10|Amgen Inc.|Kras g12c inhibitors and methods of using the same|

---

WO2019217691A1|2018-05-10|2019-11-14|Amgen Inc.|Kras g12c inhibitors for the treatment of cancer|

---

MA52765A|2018-06-01|2021-04-14|Amgen Inc|KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE|

---

CA3099799A1|2018-06-11|2019-12-19|Amgen Inc.|Kras g12c inhibitors for treating cancer|

---

MA51848A|2018-06-12|2021-04-21|Amgen Inc|KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE|

---

BR112020026641A2|2018-06-27|2021-03-30|Oscotec Inc.|PYRIDOPYRIMIDINONE DERIVATIVES FOR USE AS AXL INHIBITORS|

---

AU2019310590A1|2018-07-26|2021-01-14|Sumitomo Dainippon Pharma Oncology, Inc|Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same|

---

AU2019352741A1|2018-10-04|2021-05-06|Assistance Publique-Hôpitaux De Paris |EGFR inhibitors for treating keratodermas|

---

JP2020090482A|2018-11-16|2020-06-11|アムジエン・インコーポレーテツド|Improved synthesis of key intermediate of kras g12c inhibitor compound|

---

JP2020105162A|2018-11-19|2020-07-09|アムジエン・インコーポレーテツド|Combination therapy including kras g12c inhibitor and one or more additional pharmaceutically active agents for treatment of cancers|

---

JP2022507527A|2018-11-19|2022-01-18|アムジエン・インコーポレーテツド|KRAS G12C inhibitor and its usage|

---

AU2019391097A1|2018-12-04|2021-05-20|Sumitomo Dainippon Pharma Oncology, Inc.|CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer|

---

EP3898626A1|2018-12-19|2021-10-27|Array Biopharma, Inc.|Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases|

---

EP3898615A1|2018-12-19|2021-10-27|Array Biopharma, Inc.|7-amino)quinoxaline derivatives as fgfr inhibitors for treating cancer|

---

SG11202106520VA|2018-12-20|2021-07-29|Amgen Inc|Kif18a inhibitors|

---

CA3123227A1|2018-12-20|2020-06-25|Amgen Inc.|Heteroaryl amides useful as kif18a inhibitors|

---

CA3123042A1|2018-12-20|2020-06-25|Amgen Inc.|Kif18a inhibitors|

---

AU2019401495A1|2018-12-20|2021-06-24|Amgen Inc.|Heteroaryl amides useful as KIF18A inhibitors|

---

WO2020160375A1|2019-02-01|2020-08-06|Glaxosmithkline Intellectual Property Development Limited|Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof|

---

AU2020232242A1|2019-03-01|2021-09-09|Revolution Medicines, Inc.|Bicyclic heteroaryl compounds and uses thereof|

---

CA3130083A1|2019-03-01|2020-09-10|Revolution Medicines, Inc.|Bicyclic heterocyclyl compounds and uses thereof|

---

KR20210141621A|2019-03-22|2021-11-23|스미토모 다이니폰 파마 온콜로지, 인크.|Compositions comprising PKM2 modulators and methods of treatment using same|

---

WO2020236947A1|2019-05-21|2020-11-26|Amgen Inc.|Solid state forms|

---

CA3143211A1|2019-06-26|2020-12-30|Glaxosmithkline Intellectual Property Development Limited|Il1rap binding proteins|

---

CA3147272A1|2019-08-02|2021-02-11|Amgen Inc.|Kif18a inhibitors|

---

CA3146693A1|2019-08-02|2021-02-11|Amgen Inc.|Kif18a inhibitors|

---

CA3147276A1|2019-08-02|2021-02-11|Amgen Inc.|Kif18a inhibitors|

---

CA3147451A1|2019-08-02|2021-02-11|Amgen Inc.|Kif18a inhibitors|

---

WO2021046293A1|2019-09-06|2021-03-11|Glaxosmithkline Intellectual Property Development Limited|Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab|

---

WO2021043961A1|2019-09-06|2021-03-11|Glaxosmithkline Intellectual Property Development Limited|Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy|

---

WO2021081212A1|2019-10-24|2021-04-29|Amgen Inc.|Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer|

---

TW202132316A|2019-11-04|2021-09-01|美商銳新醫藥公司|Ras inhibitors|

---

TW202132315A|2019-11-04|2021-09-01|美商銳新醫藥公司|Ras inhibitors|

---

TW202132314A|2019-11-04|2021-09-01|美商銳新醫藥公司|Ras inhibitors|

---

US20210139517A1|2019-11-08|2021-05-13|Revolution Medicines, Inc.|Bicyclic heteroaryl compounds and uses thereof|

---

WO2021097207A1|2019-11-14|2021-05-20|Amgen Inc.|Improved synthesis of kras g12c inhibitor compound|

---

WO2021097212A1|2019-11-14|2021-05-20|Amgen Inc.|Improved synthesis of kras g12c inhibitor compound|

---

WO2021108683A1|2019-11-27|2021-06-03|Revolution Medicines, Inc.|Covalent ras inhibitors and uses thereof|

---

WO2021142026A1|2020-01-07|2021-07-15|Revolution Medicines, Inc.|Shp2 inhibitor dosing and methods of treating cancer|

---

WO2021152495A1|2020-01-28|2021-08-05|Glaxosmithkline Intellectual Property Development Limited|Combination treatments and uses and methods thereof|

---

WO2021155006A1|2020-01-31|2021-08-05|Les Laboratoires Servier Sas|Inhibitors of cyclin-dependent kinases and uses thereof|

---

WO2021178296A1|2020-03-02|2021-09-10|Turning Point Therapeutics, Inc.|Therapeutic uses of macrocyclic compounds|

---

WO2021257736A1|2020-06-18|2021-12-23|Revolution Medicines, Inc.|Methods for delaying, preventing, and treating acquired resistance to ras inhibitors|

法律状态:
2011-04-21| FGA| Letters patent sealed or granted (standard patent)|

---

2011-05-26| NC| Extension of term for standard patent requested (sect. 70)|Free format text: PRODUCT NAME: TYKERB LAPATINIB Filing date: 20070628 |

---

2011-08-11| GD| Licence registered|Name of requester: SMITHKLINE BEECHAM |

---

2012-03-29| NDA| Extension of term for standard patent accepted (sect.70)|Free format text: PRODUCT NAME: TYKERB LAPATINIB Filing date: 20070628 |

---

2012-08-30| NDB| Extension of term for standard patent granted (sect.76)|Free format text: PRODUCT NAME: TYKERB LAPATINIB Filing date: 20070628 Extension date: 20220628 |

---

2017-04-27| PC| Assignment registered|Owner name: NOVARTIS AG Free format text: FORMER OWNER(S): GLAXOSMITHKLINE LLC |

优先权:

---

申请号 | 申请日 | 专利标题

---

GBGB9800569.7A|GB9800569D0|1998-01-12|1998-01-12|Heterocyclic compounds|

---

GB9800569||1998-01-12||

---